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“We live in a completely interdependent world, which 
simply means we cannot escape each other. 
How we respond to AIDS depends, in part, on whether 
we understand this interdependence. 
It is not someone else's problem. 
This is everybody's problem.” 
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Background: Individuals infected with the human immunodeficiency virus 
(HIV) are at increased risk of developing ischaemic stroke. The reasons for 
this are multifactorial, but HIV-associated vasculopathy is a potentially 
important cause. HIV-induced chronic inflammation may initiate endothelial 
dysfunction or accelerate vascular injury from other disease processes. Viral 
proteins such as the transactivator of transcription (Tat) are emerging role-
players in HIV disease pathogenesis and have a putative role in HIV-
associated endothelial dysfunction. Tat has paracrine pro-inflammatory 
effects, but its role in HIV-related stroke has not yet been investigated. 
 
Aims: The primary aim of this study was to determine whether specific Tat 
amino acid variants are associated with ischaemic stroke and biomarkers of 
inflammation and endothelial dysfunction in a group of HIV-1 subtype-C-
infected individuals. In order to do so, I first determined the aetiology of stroke 
in these participants using clinical, biochemical and neuro-imaging data. A 
secondary aim of the study was to identify any HIV-related and/or other 
traditional stroke-related risk factors that might independently or cumulatively 
increase stroke risk. For comparison, these putative risk factors were also 
determined in a group of age-matched HIV-infected non-stroke controls.  
Finally, I aimed to identify any HIV-related factors and/or Tat amino acid 
variants that might distinguish strokes due to HIV-associated vasculopathy 
from other mechanisms of stroke.    
 
Methods: A case-control study was performed on 58 Subtype-C HIV-infected 
individuals with acute ischaemic stroke and 71 HIV-1 Subtype-C-infected non-
stroke controls. Clinical, demographic, laboratory and imaging data were used to 
determined baseline differences between groups and to distinguish different 
stroke aetiologies. Exon 1 of the HIV-1 Tat protein was sequenced from peripheral 
blood samples of stroke participants and controls and amino acid variants were 
identified using viral epidemiology signature pattern analysis. Regression 
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analyses were used to examine the correlation between residues at signature 
positions with biomarkers of inflammation and endothelial activation.  
 
Results: Stroke and control groups were mostly young (mean age 33 years) 
females (62.1% & 71.8%), and of Black African ancestry. The strokes showed a 
higher prevalence of some traditional cardiovascular risk factors. Individuals with 
strokes had a higher prevalence of antiretroviral treatment interruption (25.9% vs 
0.0%, p= 0.003), lower CD4 nadir (112 vs 177.5 cells/µl, p=0.008) and CD4 count 
(208.5 vs 322.5 cells/µl, p=0.012) than controls. Median viral loads were elevated 
in both strokes and controls (4.58 & 4.13 log10 copies/ml, p=0.28). The most 
common causes of stroke were HIV-associated vasculopathy (43.1%) and 
opportunistic infections (22.4%). Two amino acid variants (proline at position 21 
and histidine at position 29) were associated with acute ischaemic stroke. These 
positions were also associated with modulation of plasma interleukin 6 and 
monocyte chemoattractant protein 1 levels. Threonine at position 58 distinguished 
strokes due to alternative mechanisms from strokes due to HIV-associated 
vasculopathy.  
 
Conclusions: Two Tat protein amino acid variants are associated with stroke in 
HIV. The precise mechanisms by which these associations occur are not known. 
However, they are likely to be part of a multiple-hit phenomenon in HIV stroke 
pathogenesis. Tat-mediated inflammation with endothelial dysfunction, HIV 
disease severity, treatment interruption and conventional cardiovascular risk 
factors probably all contribute to stroke aetiology. Thus, a multi-modal approach 
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CHAPTER ONE: INTRODUCTION  
 
 
There are currently 36.7 million people living with the human 
immunodeficiency virus (HIV) worldwide. In 2016, one million individuals 
succumbed to Acquired Immunodeficiency Syndrome (AIDS)-related 
illnesses. As a result of the increasing effectiveness and availability of 
antiretroviral therapy, AIDS-related deaths have fallen by 48% since their 
zenith in 2005 (UNAIDS, 2017). However, the advent of antiretroviral therapy 
(ART) has changed the natural progression of the disease. As the HIV-infected 
population ages, and the incidence of AIDS-defining conditions declines, non-
communicable diseases, such as HIV-associated cardiovascular disease, 
have emerged as new challenges.  
 
HIV-infected individuals are at increased risk of cardiovascular disease and 
ischaemic stroke in comparison to the HIV-uninfected population. The 
pathogenesis of stroke in HIV is multi-factorial, and stroke aetiology has been 
associated with traditional cardiovascular risk factors, opportunistic infections, 
cardio-thromboembolism and coagulopathies. In recent years, HIV has been 
observed to be an independent risk factor for stroke. The chronic persistent 
inflammatory state seen in most HIV-infected individuals may play an 
important role in endothelial dysfunction and the development of ischaemic 
stroke.  
 
HIV-associated vasculopathy is a term used to describe endothelial damage 
and dysfunction caused directly or indirectly by HIV (Benjamin et al., 2012). 
HIV-induced inflammation disrupts the physiology of normal endothelium, 
increasing the risk of vessel thrombosis and occlusion. HIV-associated 
vasculopathy is not yet well-understood, but HIV type 1 (HIV-1) proteins are 
postulated to contribute to the chronic persistent inflammation that results in 
endothelial dysfunction (Kline & Sutliff, 2008; Benjamin et al., 2012; Pillay, 
Ramdial & Naidoo, 2015).  
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Research into various HIV-1 proteins has revealed that each may have unique 
and synergistic mechanisms of promoting disease pathogenesis (Kline & 
Sutliff, 2008). Furthermore, the secretion of some HIV-1 proteins is less 
affected by antiretroviral therapy (Annunziata, 2003; Mediouni et al., 2012), 
which may account for the persistently elevated risk of cardiovascular disease 
in effectively treated individuals. Work on the Viral protein R (Vpr) and 
Transactivator of Transcription (Tat) proteins in HIV-associated neurocognitive 
disorders (HAND) has highlighted that viral proteins may have a prominent role 
in HIV-associated disease pathogenesis (Tilghman et al., 2014; Dampier et al., 
2017).   
 
Viral protein toxicity is a putative mechanism for the direct action of HIV on 
vascular endothelium. The Tat protein has multiple extra-cellular effects which 
could contribute to HIV-associated vasculopathy. Induction of pro-
inflammatory molecules, upregulation of arterial wall remodelling, and 
promotion of oxidative stress are all mechanisms which may disturb the 
physiology of normal endothelium and alter stroke risk. Amino acid mutations 
in this protein could enhance these functions and alter the susceptibility of 
certain individuals to cardiovascular disease and stroke. There is a need to 
explore the possible contribution of the Tat protein to the inflammation and 
endothelial dysfunction seen with HIV infection.  
 
South Africa (SA) is an ideal context in which to investigate the stroke risk 
posed by the virus itself. The largest burden of HIV is borne by individuals aged 
15-49 (UNAIDS, 2016), most of whom have a relative paucity of conventional 
cardiovascular risk factors. Just over 50% of HIV-infected individuals in SA are 
on antiretroviral treatment (UNAIDS, 2016), which allows for the study of 
individuals who are either treatment-naïve, recently initiated, or well-
established on treatment. The most prevalent HIV-1 subtype in the population 
is Subtype-C, which also accounts for 52% of HIV infections globally (Ariën, 
Vanham & Arts, 2007), making this research potentially relevant to many HIV-
infected individuals worldwide.   
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Following recent work demonstrating that certain amino acid variations in Vpr 
and Tat distinguish cognitively-impaired and normal participants in HAND 
(Tilghman et al., 2014; Dampier et al., 2017), I decided to determine the amino 
acid profile of the Tat protein in young HIV-infected individuals with acute 
ischaemic stroke and to compare it with the Tat protein sequences found in 
HIV-infected non-stroke controls. At the time of writing, I believe that this is the 
first study examining the Tat protein in the context of acute ischaemic stroke.  
 
I undertook a case-control study of young HIV-infected individuals with acute 
ischaemic stroke, comparing them with HIV-infected non-stroke controls. My 
intention was to analyse both the clinical and virological characteristics of this 
cohort, in order to further the understanding of endothelial dysfunction in HIV, 
and the multiple factors that may determine the progression of endothelial 
dysfunction to the critical threshold of thrombosis and occlusion. The primary 
focus of this study was to examine the genetic attributes of the Tat protein in 
this cohort, to see if there were amino acid differences that distinguished the 
stroke group from the controls, as well as to determine the effect of any 

















CHAPTER TWO: BACKGROUND AND RATIONALE 
FOR STUDY 
 
2.1 Introduction to the rationale for the study  
 
This chapter provides an overview of the relationship between ischaemic 
stroke and HIV infection. It explains the current understanding of the 
pathogenesis and role of HIV-related endothelial dysfunction and HIV-
associated vasculopathy in HIV-associated young stroke. The importance of 
biomarkers of inflammation and endothelial activation as a reflection of 
endothelial dysfunction is introduced, as well as the profile of these biomarkers 
in HIV infection. The specific focus of this chapter is the potential role of the 
Transactivator of Transcription protein in promotion of endothelial dysfunction, 
and I cover the mechanisms by which the Tat protein could contribute to 
elevation of specific biomarkers, endothelial injury, and stroke. Furthermore, I 
look at genetic variation in HIV, specifically the pathogenic effects of amino 
acid variations in HIV-1 proteins. I note also that this research took place in the 
South African context, which is the epicentre of the HIV epidemic, and has a 
high prevalence of HIV-1 Subtype C.  
2.2 Ischaemic Stroke   
 
2.2.1 Epidemiology of stroke worldwide and in South Africa   
Stroke is a global health problem. It is the second leading cause of death and 
the third leading cause of Disability-Adjusted Life Years (DALYs) worldwide 
(Murray et al., 2012). It is also a growing problem in South Africa. Stroke was 
the second leading cause of natural death in SA in 2014, and in 2008, 
contributed 564 000 DALYs to the country’s burden of disease (Bertram et al., 
2013; Statistics South Africa, 2015).  Ischaemic stroke accounts for the majority 
of the stroke burden. In recent years, ischaemic strokes comprised 54%-85% 
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and 73%-90% of all recorded strokes in developing and high-income countries 
respectively (Feigin et al., 2009).  
 
2.2.2 Pathogenesis of ischaemic stroke 
Ischaemic stroke results from thrombo-embolic occlusion of extra- and intra-
cranial arteries supplying the brain. Embolic occlusion includes that from a 
cardiac source, or artery-to-artery embolism from a diseased or dissected 
artery. Risk factors for ischaemic stroke initiate a process that leads to injury 
and dysfunction of vascular wall endothelium. This culminates in thrombosis 
and occlusion of vessels. Intact and healthy endothelium maintains vascular 
integrity and homeostasis, exerting major protective effects by regulating 
vasoconstriction, fibrinolysis, vasodilation, smooth muscle proliferation, and 
thrombogenesis (Bonetti, 2003).  
 
2.2.3 Endothelial dysfunction in stroke  
The impairment of endothelial function often results from physical shear stress, 
damage by reactive oxygen species and exposure to pro-inflammatory 
cytokines (Poggesi et al., 2016). Consequently, the endothelium can no longer 
balance “endothelium-derived relaxing factors”, which promote vasodilation 
and prevent thrombus formation (Furchgott & Zawadzki, 1980; Flammer & 
Lüscher, 2010), and “endothelium-derived contracting factors” (Luscher et al., 
1992), which have the opposite effect. Endothelial dysfunction results in 
ischaemia and stroke when the imbalance reaches a threshold that produces 





2.2.4 Traditional cardiovascular risk factors in stroke pathogenesis  
In HIV-uninfected individuals, traditional cardiovascular risk factors, such as 
hypertension, diabetes, dyslipidaemia, smoking and obesity are pro-
atherogenic, and the principal contributors to ischaemic stroke (Sacco et al., 
2006; O’Donnell et al., 2016). The primary mechanisms for stroke in the 
presence of these risk factors are inflammation and oxidative stress. 
Endothelial dysfunction results from the initiation and maintenance of chronic 
inflammatory processes and production of reactive oxygen species (Libby, 
2002; Widlansky et al., 2003). Traditional cardiovascular risk factors promote 
high levels of free radicals and other oxidising molecules. This causes 
structural damage to cellular components, alters secondary messenger 
systems and activates various transcription factors. Oxidative stress also 
depletes nitric oxide, which is crucial for vasodilation, downregulates adhesion 
molecule expression, and inhibits platelet aggregation and leukocyte adhesion 
to the vascular wall (Cai & Harrison, 2000; Li, Horke & Förstermann, 2014).  
The most common stroke subtypes in individuals with these risk factors are 
large artery atherosclerosis and small vessel occlusion (Chung et al., 2014).   
 
2.3 HIV infection and stroke    
 
2.3.1 Epidemiology of HIV infection in South Africa  
South Africa is the epicentre of the global HIV epidemic. The number of 
infected individuals in the country constitutes 19% of the total number of 
people with HIV worldwide. 15% of new infections and 11% of all AIDS-related 
deaths occur in SA (UNAIDS, 2016).   
 
HIV-related mortality and morbidity are a significant burden to the health care 
system in South Africa. In 2014, HIV infection was the fifth leading cause of 





Figure 2.1. Epidemiology of HIV infection in South Africa. Statistics adapted from (UNAIDS, 
2016). Abbreviations: PLWH, people living with HIV; ART, antiretroviral therapy; VL, viral load  
 
2.3.2 Indicators of HIV disease severity  
Measures of the severity of HIV disease include the peripheral blood cluster of 
differentiation 4 (CD4) T-lymphocyte count and the HIV-1 ribonucleic acid 
(RNA) viral load. The CD4 count is a measure of the stage and progression of 
disease. The viral load quantifies the concentration of peripheral blood HIV-1 
RNA, in copies/millilitre (ml). Viral load provides an estimation of the degree of 
systemic viral replication in addition to demonstrating the effectiveness of 
antiretroviral therapy.  
 
2.3.3 The link between HIV and stroke  
SA is in the midst of a transition between health problems common to 
developing countries and those of the developed world. Two components of 
the quadruple disease burden unique to SA are infectious disease, including 
HIV, and non-communicable disease, which includes stroke (Mayosi et al., 
2012; South African Department of Health, 2014). Research has demonstrated 








































(CVD) (Islam et al., in press; Tripathi et al., 2014). Furthermore, there is a 
growing body of evidence showing an association between HIV and stroke.  
 
Stroke in HIV-infected individuals was initially reported in the 1980s (Anders 
et al., 1985). Studies from the both the pre- and post-antiretroviral era 
demonstrate that HIV-infected individuals have an increased risk of stroke, 
especially ischaemic stroke, in comparison with HIV-uninfected controls 
(Engstrom, Lowenstein & Bredesen, 1989; Qureshi et al., 1997; Cole, 2003; 
Ovbiagele & Nath, 2011; Rasmussen et al., 2011; Chow et al., 2012; Mateen 
et al., 2013; Sico et al., 2015).  Incidence-rate estimates (1.25 vs 0.74; 2.79 vs 
2.24 and 5.27 vs 3.75 per 1000 person years), are consistently higher in HIV-
infected persons compared to HIV-uninfected individuals (Chow et al., 2012; 
Marcus et al., 2014; Sico et al., 2015), with the same studies reporting hazard 
ratios for stroke of 1.17 and 1.40.  
 
With improved availability of ART, the prevalence of cardiovascular conditions 
associated with advanced HIV disease, such as dilated cardiomyopathy, has 
declined. However, the relative prevalence of stroke has increased (Subsai et 
al., 2006; Ovbiagele & Nath, 2011; Feinstein et al., 2016). Some authors 
estimate that the rate of stroke in people well-established on ART may be 
similar to the pre-ART era (Arentzen et al., 2015).  
 
Stroke and central nervous system (CNS) complications are a significant and 
complex problem in people living with HIV (Power et al., 2012; McArthur & 
Smith, 2013; Bhatia & Chow, 2016). Cardiovascular events, including 
cerebrovascular disease, pose the greatest risk of mortality to people on ART 
(Reisler et al., 2003). Consequently, much research in recent years has 
focused on the risk factors and aetiology of stroke in HIV. Development of 
effective adjunctive treatment which complements antiretroviral therapy may 
prove essential to combat the cardiovascular and neurological disease burden 





2.3.4 Aetiology and pathogenesis of stroke in HIV infection   
The pathogenesis of ischaemic stroke in HIV-infected people, in the absence 
of easily identifiable causes such as meningitis and cardiac disease, is 
complex and multifactorial. Ischaemic stroke in HIV is likely due to the 
synergistic effect of multiple factors. Research into HIV and stroke, including 
prior research on individuals from this cohort, suggests that continual or 
cumulative exposure to a variety of risk factors may cause progression of 
endothelial dysfunction to a threshold at which thrombosis and occlusion 
occurs (Maggi, Ingrassia & D’Annunzio, 2008; Allie, 2013). The overview of 
the predominant risk factors presented below highlights a common underlying 
mechanism: inflammation.  
 
2.3.4.1 Contribution of HIV to the metabolic syndrome 
 
Untreated HIV infection is associated with adverse metabolic profiles such as 
dyslipidaemia and impaired glucose metabolism. In treated individuals, the 
metabolic effects of HIV, in combination with traditional risk factors and certain 
antiretroviral agents, may promote metabolic syndrome, which in turn 
increases the risk of stroke (El-Sadr et al., 2005; Alberti et al., 2009; Krishnan 
et al., 2012; Willig & Overton, 2016; Non, Escota & Powderly, 2017).   
 
2.3.4.2 Antiretroviral therapy and stroke risk  
 
In the past, antiretroviral therapy was associated with metabolic side effects 
and increased risk of cardiovascular disease (The Data Collection on Adverse 
Events of Anti-HIV Drugs (DAD) Study Group, 2003; Venter & Sanne, 2003). 
However, newer evidence suggests that this risk may be confined to older 
protease inhibitors, and is not increased in those on newer nucleoside reverse 
transcriptase inhibitors (NRTIs) such as Tenofovir and Lamivudine (Worm et 
al., 2010; Eholié et al., 2015). Furthermore, a specific association between 
modern ART and stroke is less well-proven than the association of ART with 
cardiovascular disease as a whole (Chow et al., 2012; Vinikoor et al., 2013).   
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2.3.4.3 Traditional cardiovascular risk factors and the concept of 
accelerated atherosclerosis in HIV-associated stroke  
 
In the developed world, the increased incidence of HIV-associated stroke may 
partly be explained by an ageing population of HIV-infected individuals, in 
whom there is a high prevalence of cardiovascular risk factors (Escárcega et 
al., 2014). In higher income countries, hypertension, dyslipidaemia, smoking, 
diabetes and substance use are common in HIV-infected populations (Triant 
et al., 2007; Corral et al., 2009). Researchers in developed countries find that 
the aetiology of HIV-associated stroke more frequently mirrors that of 
ischaemic stroke in the general population: an adverse conventional 
cardiovascular risk profile resulting in atherosclerotic vasculopathy. In an 
American cohort of 2515 HIV-infected individuals, two-thirds of those with 
stroke were over the age of 40. Atherosclerosis and small vessel disease 
accounted for 77% of ischaemic strokes (Vinikoor et al., 2013).   
 
However, whilst traditional cardiovascular risk factors do indeed play a role, 
their contribution may be less prominent than that of HIV itself. The 
Framingham Risk Score for Stroke (Framingham Heart Study, 2017), which 
uses classical cardiovascular risk factors to predict the 10-year risk of stroke 
in asymptomatic individuals, has been shown to underestimate the stroke risk 
in HIV-infected people (Mateen et al., 2013). Even after adjustment for 
traditional risk factors, HIV-infected individuals have an increased rate of CVD 
compared to those without HIV infection (Triant et al., 2007; Chow et al., 2012). 
Furthermore, many young people with HIV develop stroke in the absence of 
hypertension, hyperlipidaemia, smoking, diabetes and concomitant CVD 
(Connor, 2007; Ortiz et al., 2007). The Data-collection on Adverse Effects of 
Anti-HIV Drugs (D:A:D) study has more recently developed a model which 
includes CD4 count and ART exposure, thus improving model prediction 
compared to more conventional risk scores (Friis-Møller et al., 2016). This 
suggests that additional mechanisms other than traditional cardiovascular risk 
factors play a more prominent role in the pathogenesis of HIV-related stroke.  
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Increasing recognition of the role of the virus is evident in recent reviews of 
HIV-associated cardiovascular disease. There is an acknowledgement that 
whilst traditional risk factors are important, HIV itself contributes significantly 
to stroke and other cardiovascular diseases (Escárcega et al., 2014; Feinstein 
et al., 2016). A “two-step hypothesis” has been proposed for cardiovascular 
disease in HIV. The first step involves various degrees of inflammation initiated 
by HIV itself, which then progresses to a second step of accelerated 
atherosclerosis, from the synergistic effect of more classical and well-
recognised risk factors, such as hypertension, smoking and diabetes (Maggi, 
Ingrassia & D’Annunzio, 2008).  
 
2.3.4.4 HIV as an independent risk factor for stroke  
 
HIV is now recognised as an independent risk factor for stroke. This 
association may be even stronger for HIV-infected individuals under the age 
of 45 years, in whom conventional cardiovascular risk factors are less 
prominent (Engstrom, Lowenstein & Bredesen, 1989; Chow et al., 2012; 
Benjamin, Corbett, et al., 2016). More advanced HIV disease, with low CD4 
counts and high viral loads, is positively correlated with risk of incident CVD 
and stroke (Siedner, in press; The Data Collection on Adverse Events of Anti-
HIV Drugs (DAD) Study Group, 2003; Lichtenstein et al., 2010; Chow et al., 
2012; Sico et al., 2015). In developing countries, well-recognised causes of 
HIV-associated stroke in young people are coagulopathy, opportunistic 
infections and cardio-embolism, the mechanisms for which are fairly well 
understood. However, HIV-associated vasculopathy is emerging as an 
important stroke phenotype in HIV, and there is still much to be explored with 








2.3.5 HIV-associated vasculopathy  
In HIV-infected individuals with stroke, HIV-associated vasculopathy is a term 
used to define “any abnormality” of cerebral vasculature that can be attributed 
“directly or indirectly to HIV” (Connor, 2007; Benjamin et al., 2012). It has 
recently been defined to encompass a range of phenotypes, including 
accelerated atherosclerotic vasculopathy, HIV-associated vasculitis, small 
vessel disease and non-atherosclerotic vasculopathy. Notably, HIV-
associated vasculopathy occurs in the absence of vasculitis due to 
opportunistic infections. The various phenotypes can be diagnosed with a 
combination of imaging, serology, cerebrospinal fluid (CSF) analysis and 
histopathological examination of brain tissue, once other important known 
causes of stroke have been excluded (Benjamin et al., 2012, 2017; Benjamin, 
Bryer, et al., 2016).  
 
2.3.5.1 Histopathology of HIV-associated vasculopathy  
 
HIV-associated vasculopathy affects extra- and intra-cranial vessels of all 
sizes, producing a range of pathological changes. One of the best-
characterised is aneurysmal enlargement and occlusion of large- and medium- 
sized vessels, which may be accompanied by cerebral infarction (Chetty, 
Batitang & Nair, 2000; Chetty, 2001).  
 
Other documented pathological changes include leucocytoclastic vasculitis of 
the vasa vasorum and peri-adventitial vessels, stenosis and thrombotic 
occlusion, elastic lamina fragmentation, neovascularisation and accelerated 
atherosclerosis (Benjamin et al., 2012).   
 
Small vessel changes, thought to be asymptomatic, have been characterized 
on autopsy of HIV-infected individuals. Histopathological features include 
cerebral micro-infarcts, hyaline wall thickening of small vessels, dilatation of 
perivascular spaces, pigment deposition with vessel wall mineralization and 
perivascular inflammatory cell infiltrates (Connor et al., 2000). 
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2.3.5.2 Proposed mechanisms for HIV-associated vasculopathy  
The pathogenesis of HIV-associated vasculopathy is thought to be related to 
virus-induced endothelial damage and dysfunction, which contributes to the 
pathogenesis of thrombosis and occlusion. Figure 2.2 illustrates the proposed 
mechanisms for pathological changes seen in HIV-associated vasculopathy. 
These processes induce a pro-inflammatory state that disrupts the physiology 
of normal endothelium.  
 
In HIV infection, the vascular endothelium is subjected to direct and indirect 
injury from the virus and its sequelae. Mechanisms of direct injury include 
exposure to virions and toxic viral proteins, pro-inflammatory cytokines, and 
infected HIV-tropic cells such as monocytes, macrophages, and CD4+ T-
lymphocytes. This culminates in chronic persistent inflammation, similar to that 
propagated by conventional cardiovascular risk factors. Activation of 
endothelium increases permeability and permits monocyte invasion. There is 
“production of reactive oxygen species, expression of cell adhesion molecules 
(CAMs), and…release of chemoattractants” (Kline & Sutliff, 2008; Benjamin et 
al., 2012) The severity of HIV infection has been associated with a greater 
degree of endothelial dysfunction (Maggi, Ingrassia & D’Annunzio, 2008). 
Poorly controlled viral replication, signified by a high viral load or low CD4 
count, would likely enhance the exposure of vascular endothelium to direct 
damage from viral particles.  
 
Indirect mechanisms maintain this inflammatory state. Circulating infected 
leucocytes and monocytes continually release pro-inflammatory molecules. 
Trapped sub-endothelial monocytes release cytokines and chemokines. 
Another source of inflammation could be the immune reconstitution 








Figure 2.2. Direct and indirect damage from HIV, leading to endothelial dysfunction, 
thrombosis and occlusion.(Benjamin et al., 2012; Pillay, Ramdial & Naidoo, 2015) 
 
The combination of direct and indirect mechanisms results in persistent 
inflammation. This produces a cycle of endothelial activation and remodelling, 
promoting thrombosis and occlusion (Monsuez et al., 2009; Benjamin et al., 
2012; Paiardini & Müller-Trutwin, 2013; Pillay, Ramdial & Naidoo, 2015). 
 
2.4 Biomarkers of inflammation and endothelial 
dysfunction  
 
2.4.1 Biomarkers as a measure of inflammation and endothelial damage  
Measurement of biomarkers in the peripheral blood of individuals provides an 
indication of the degree of inflammation, endothelial dysfunction and vessel 
injury. The severity of dysfunction is positively associated with the risk of a 
cardiovascular event (Widlansky et al., 2003). Levels of pro-inflammatory and 
endothelial activation biomarkers in people with HIV may therefore indicate the 





2.4.2 Biomarkers of inflammation and endothelial dysfunction in HIV 
Biomarkers of endothelial activation, dysfunction, inflammation and 
haemostasis are persistently elevated in people with HIV. This would suggest 
that all HIV-infected individuals are subject to a spectrum of endothelial 
dysfunction, which could range from sub-clinical changes to overt vessel wall 
disease.  
 
These biomarkers include highly sensitive C-reactive protein (hsCRP), D-
dimers, interleukin-6 (IL-6), serum CD163, asymmetric dimethylarginine, 
monocyte chemoattractant protein 1 (MCP-1), adhesion molecules, and 
soluble CD14 (Coll et al., 2006; Melendez et al., 2008; Neuhaus et al., 2010; 
Burdo et al., 2011; Armah et al., 2012; Baker et al., 2012; Graham et al., 2013; 
Wada et al., 2015). These international studies showing persistent elevation 
of pro-inflammatory and endothelial activation biomarkers reflect the chronic 
pro-inflammatory milieu that is characteristic of HIV infection. The African and 
South-African context is no different. High levels of inflammatory biomarkers 
have been detected in both treated and treatment-naive African and South-
African HIV-infected individuals (Fourie et al., 2011, 2015; Graham et al., 
2013).   
 
Chronic inflammation with persistent elevation of biomarkers likely contributes 
to HIV-associated vascular disease. Elevated IL-6, for example, is 
independently associated with an increased risk of cardiovascular disease and 
stroke in HIV-infected individuals (Duprez et al., 2012; Tenorio et al., 2014). 
IL-6 and tumour necrosis factor-alpha (TNF-a) enhances transcription and 
replication of HIV (Breen, 2002).  This creates a positive-feedback mechanism 
that increases endothelial exposure to viral stimuli.  
 
2.4.3 Inflammation and endothelial dysfunction in the antiretroviral era  
 
HIV disease severity is positively correlated with biomarkers of endothelial 
dysfunction and inflammation (De Larrañaga et al., 2003). However, complete 
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normalisation of various biomarkers does not occur with initiation of 
antiretroviral therapy (Torriani et al., 2008; Arildsen et al., 2013; Paiardini & 
Müller-Trutwin, 2013; O’Halloran et al., 2015).  
 
In fact, systemic inflammation, immune activation and vascular injury persist, 
albeit at lower levels, in virally-suppressed HIV-infected individuals (French et 
al., 2009; d’Ettorre et al., 2016; Longenecker, Sullivan & Baker, 2016). Whilst 
ART does reduce cardiovascular risk in treated individuals, compared with 
those who are treatment-naïve, an elevated CVD risk remains (The Strategies 
for Management of Antiretroviral Therapy (SMART) Study Group, 2006; Corral 
et al., 2009; Chow et al., 2012).  
 
This suggests that endothelial damage and inflammation in HIV is not 
completely dependent on active viral replication. This is where the role of viral 
proteins may come to the fore (Kline & Sutliff, 2008; Pillay, Ramdial & Naidoo, 
2015). Whilst ART suppresses active viral replication, it may not significantly 
reduce viral protein secretion. Thus, continual exposure of vascular 
endothelium to toxic viral proteins may be a plausible explanation for the 
increased cardiovascular risk seen in both treated and untreated individuals 
(Annunziata, 2003; Mediouni et al., 2012). 
 
2.5 HIV-1 proteins and endothelial dysfunction  
 
It is currently unclear whether endothelial cells can be directly or productively 
infected by HIV (Bissel & Wiley, 2004). However, secreted HIV-1 proteins 
interact with endothelium, promoting endothelial damage, dysfunction and 
remodelling (Kanmogne, Kennedy & Grammas, 2002; Mu et al., 2007; Kline & 
Sutliff, 2008). Several HIV-1 proteins have been implicated in endothelial 
injury. Of particular interest are the regulatory and accessory proteins, such as 
the Tat protein, Negative factor (Nef) and Viral protein R (Kline & Sutliff, 2008; 
Wang et al., 2015).  
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Although all three proteins have plausible mechanisms for promoting 
endothelial injury, the activation of inflammatory pathways in endothelial cells 
has been primarily attributed to the effects of the Tat protein (Mu et al., 2007).  
2.5.1 Classification and function of HIV-1 proteins  
The HIV-1 genome consists of nine genes, encoding fifteen viral proteins. 
Structural proteins that make up the virion core and envelope are encoded by 
gag. The pol proteins provide the enzymatic functions necessary for reverse 
transcription, integration and proteolytic processing. The remaining six 
proteins are classified as regulatory or accessory, depending on their 
individual functions (Frankel & Young, 1998).  
 






Gene Protein Description/Function 
gag MA Matrix protein  
CA Core capsid protein 
NC Nucleocapsid protein 
env SU (gp120) Surface glycoprotein 
TM (gp 41) Transmembrane protein 
pol Protease Virus maturation  
Reverse Transcriptase Reverse transcribes viral RNA 
Integrase Integrates proviral DNA into host DNA 
tat Tat Transactivator of HIV gene expression 
rev Rev Expression of structural proteins 
vif Vif Virion maturation & infectivity 
vpr Vpr Inhibits cell division & promotes nuclear 
localization  
vpu Vpu Extracellular release of viral particles  
nef Nef Down-regulates CD4 & MHC Class I 






































2.6  The HIV-1 Transactivator of Transcription Protein  
 
2.6.1 Introduction to the Transactivator of Transcription protein 
I chose to focus on the Tat protein as a potentially important contributor to 
endothelial dysfunction in HIV. This is due to its critical role in the proliferative 
capacity of the virus, as well as its paracrine pro-inflammatory effects that have 
been demonstrated in vitro. The paracrine effects on vascular endothelium in 
vivo may work synergistically with various risk factors to produce clinical 
effects such as ischaemia.  
 
2.6.2 Structure and primary function of the Tat protein 
 
 
The Tat protein initiates and promotes full elongation of HIV-1 RNA transcripts. 
The protein is an 86 to 101 amino acid (aa) polypeptide encoded by two exons. 
The first exon is a 72-aa peptide that is necessary for transactivation (Caputo 
et al., 1995; Chang, Gallo & Ensoli, 1995). The second exon, containing a 
tripeptide Arginine-Glycine-Aspartic acid (RGD)-motif, confers structural 
stability and supports interaction with transcriptional factors. It may support  
improved binding of the Tat protein to endothelial cells and other cell types, 
and contribute to attenuation of the innate immune response to the virus 
(Brake, Debouck & Biesecker, 1990; Jeang, Xiao & Rich, 1999; Lopez-Huertas 
et al., 2010; Kukkonen et al., 2014).   
Figure 2.3. The HIV-1 Genome Map. The tat exon 1, position 5831-6045, is highlighted in 
charcoal grey, on the second reading frame. The tat exon 2 is also in charcoal grey, on the first 
reading frame (http://www.hiv.lanl.gov). 
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In the absence of Tat, the 5’ long terminal repeat (LTR) is a “defective 
promoter” (Karn, 2000). Premature termination of transcript elongation is 
common. Without Tat, many nascent RNA transcripts terminate within the first 
500 nucleotides (Marciniak & Sharp, 1991). Tat is one of the first proteins to 
be expressed by infected cells, and binds to the transactivator response 
element (TAR) at the 5’ end of new HIV-1 RNA transcripts (Rana & Jeang, 
1999; Bagashev & Sawaya, 2013). Binding of Tat to TAR then recruits several 
transcription factors. Cooperation with these factors stimulates initiation and 
full elongation of transcripts by RNA polymerase II. During early transcription 
elongation, Tat abrogates promoter-proximal pausing of RNA-polymerase II 
and dramatically enhances synthesis of full-length RNA transcripts. This 
effectively upregulates the rate of HIV replication (Feng & Holland, 1988; Rana 
& Jeang, 1999; Zhou & Rana, 2002; Campbell & Loret, 2009; Reeder et al., 
2015).   
 
2.6.3 Functional domains of the HIV-1 Tat protein  
 
The amino acid sequence encoded by exon 1 has several functional domains, 
as depicted in Figure 2.4. Domain I (aa 1-21) is the N-terminal, which is a 
proline-rich, acidic region. Domains II (aa 22-37) and III (aa 38-48) are the 
cysteine-rich and core regions respectively. Domain IV (aa 49-57) and Domain 
V (aa 58-72), are the arginine- and glutamine-rich domains. Domains IV and 
1-72 73-101 
Exon 1 Exon 2 
  N C 
1-21 
 


















Chemotactic Domain (aa 24-51)  





Figure 2.4. Functional domains of the Tat protein. Adapted from (Cowley et al., 2011; Roy et 
al., 2015; BioAfrica, 2017) 
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V (aa 49-72) are together considered to be the basic region (Jeang, Xiao & 
Rich, 1999; Li et al., 2012; Roy et al., 2015). Possibly due to nomenclature, 
the border between domains IV and V is unclear in the literature. Some papers 
cite Domain IV as residing between amino acid residues 49 and 57 (Demarchi, 
Gutierrez & Giacca, 1999; Mitola et al., 2000; Shojania et al., 2010; Roy et al., 
2015), whilst others extend Domain IV to include residues 58 and 59 (Rana & 
Jeang, 1999; Grégoire et al., 2001; Strebel, 2003; Campbell et al., 2004; 
Campbell & Loret, 2009; Cowley et al., 2011; Musinova et al., 2016).  
 
There are two additional regions thought to be primarily responsible for Tat’s 
chemoattractant and neurotoxic properties, referred to as the chemotactic (aa 
24-51) and neurotoxic (aa 31-61) domains respectively. In 1996, Nath et al.  
determined that a peptide fragment, containing aa 31-61 of Tat, was cytotoxic 
to human neurons, causing activation of excitatory amino acid receptors, intra-
cellular influx of calcium (Ca2+) and neuronal apoptosis (Nath et al., 1996). In 
1998, Albini et al. identified that Tat residues 24-51 had potent chemotactic 
activity, proposing that this was the predominant region with which Tat 




Table 2.2. Functional domains of the Tat protein exon 1 
 








Highly conserved sequence 
• Contributes to initiation of transcription (Siderovski et al., 1992) 
• Mediates binding to cellular response element binding protein (CREB), 
CBP/p300 complex, which cooperates with Tat to activate transcription factors 
(Deng et al., 2000; Bagashev & Sawaya, 2013; Davey et al., 2014) 












• Dimerization of Tat (Frankel et al. 1988)  
• Works synergistically with basic region to form stable homodimers mediating 
chemoattraction and migration of lymphocytes (Urbinati et al., 2009) 











• Mitogen-activated protein kinases (MAPK) & protein kinase R (PKR) activation in 
combination with basic region (Rusnati et al., 2001; Bagashev & Sawaya, 2013) 















Arginine-rich region with 
RKKRRQRRR motif 
Glutamine-rich region (subject 
to highest degree of variability) 
(Jeang, Xiao & Rich, 1999) 
 
• TAR RNA binding & interaction (Loret et al., 1992) 
• Nuclear localization signal (NLS) (Musinova et al., 2016) 
• Uptake of Tat by cells (Jeang, Xiao & Rich, 1999; Li et al., 2009) 
• Activation of nuclear factor kappa B (NF-kB) (Demarchi, Gutierrez & Giacca, 
1999) 
• Induction of TNF-a (Philippon et al., 1994) 
• Upregulation of E-selectin (Cota-Gomez et al., 2002) 
• Angiogenic (Albini et al., 1996; Barillari et al., 1999; Vene et al., 2001)  








(Cowley et al., 2011)  
• Majority of Tat’s effects on monocytes (Albini, Benelli, et al., 1998) 
• Mimics b-chemokines (Albini, Ferrini, et al., 1998) 
• Induction of IL-8 and vascular endothelial growth factor (VEGF) release from 








responsible for neurotoxic 
properties  (Nath et al., 
1996; Kruman, Nath & 
Mattson, 1998) 
• Neuronal cytotoxicity via excitatory amino acid receptor activation & alteration of 
Ca2+ levels (Nath et al., 1996) 




2.6.4 The potential contribution of the Tat protein to endothelial 
dysfunction  
 
2.6.4.1 Introduction to mechanisms by which Tat may promote endothelial 
dysfunction  
 
HIV-associated endothelial dysfunction results from multiple, simultaneous 
pathogenic processes (see Figure 2.2). These include cytokine and 
chemokine release, upregulation of adhesion molecules, increased oxidative 
stress, alteration of vascular wall structure and integrity, and an imbalance 
between vasorelaxant and vasoconstricting factors.  
 
The Tat protein’s numerous non-transcriptional activities may contribute to all 
of these processes. The Tat protein, secreted from infected cells, has 
paracrine effects on bystander infected and uninfected cells (Ensoli et al., 
1993). Endothelial cells are no exception. The Tat protein can cause a variety 
of pathogenic changes in endothelial cells, including endothelial cell apoptosis 
(Lafrenie et al., 1996; Park et al., 2001; Ma et al., 2016). Within the host cell, 
and independent of viral replication, Tat upregulates gap-junction expression. 
Pro-inflammatory molecules can then diffuse from infected cells to uninfected 
neighbouring cells (Berman et al., 2016).  Once secreted, the Tat protein can 
cross cell membranes and modulate the expression of cellular genes and 
signalling pathways involved in inflammation (Toborek et al., 2005; Cota-








2.6.4.2 Expression of pro-inflammatory mediators  
 
Tat is directly involved in the increased expression of pro-inflammatory 
molecules via NF-κB-dependent mechanisms (Nath et al., 1999; Weiss et al., 
1999; Bennasser et al., 2002; Cota-Gomez et al., 2002; Lee et al., 2004; 
Chauhan et al., 2007; Ben Haij et al., 2015).  
 
NF-κB is a potent inducer of TNF-α, interleukin-1 (IL-1), IL-6, MCP-1 and 
CD40. (Lafrenie et al., 1997; Park et al., 2001; Sui et al., 2007; Gresele et al., 
2012) CD40 has a positive feedback effect on NF-κB, sustaining the 
upregulated response (Sui et al., 2007). MCP-1 induces recruitment and 
migration of monocytes across endothelial cells (Weiss et al., 1999) and 
mediates activation of CD16+ monocytes. CD16+ monocytes may be pro-
atherogenic and an indicator of premature cardiovascular disease in younger 
HIV-infected patients (Parihar, Eubank & Doseff, 2010; Baker et al., 2014). In 
addition, Tat can directly activate interleukin-10 (IL-10) and stimulate VEGF 
receptors (Benelli et al., 2000; Gee et al., 2012).  
 
2.6.4.3 Promotion of oxidative stress  
 
The Tat protein promotes oxidative stress via several mechanisms. It 
represses manganese superoxide dismutase, increases nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidation, upregulates various inflammatory 
molecules and promotes calcium influx into the cytoplasm (Kruman, Nath & 
Mattson, 1998; Kline & Sutliff, 2008; Cota-Gomez et al., 2011).  
 
2.6.4.4 Upregulation of adhesion molecules  
 
In endothelial cells, the Tat protein upregulates expression of adhesion 
molecules such as intercellular adhesion molecule 1 (ICAM-1) and vascular 
cell adhesion molecule 1 (VCAM-1) (Dhawan et al., 1997; Liu et al., 2005). It 
also induces E-selectin via a NF-κB-dependent mechanism (Cota-Gomez et 
al., 2002).   
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2.6.4.5 Impact on vascular tone and vessel wall remodelling 
 
The Tat protein directly impacts vascular tone by decreasing the expression of 
endothelial nitric oxide synthase and upregulating expression of endothelin-1 
(ET-1), a powerful vasoconstrictor (Paladugu et al., 2003; Chauhan et al., 
2007). This imbalance between nitric oxide (the primary mediator of 
vasodilation) and ET-1, promotes vasoconstriction, which increases the risk of 
platelet aggregation and thrombosis. Additionally, in synergy with shear stress, 
the Tat protein may promote endothelial arterial wall remodelling (Parker et al., 
2014).  
 
2.6.4.6 The effect of Tat on cerebral vessels  
 
HIV-infected individuals exhibit decreased cerebrovascular reactivity in 
comparison to HIV-uninfected controls (Chow et al., 2015). Tat, possibly via 
its effects on NO and ET-1, has been shown to decrease cerebrovascular 
reactivity, which can increase the risk of cerebral ischaemia (Blaser et al., 
2002; Carrera et al., 2010; Silva et al., 2012). Tat also alters tight junction 
protein expression, increasing the permeability of the blood brain barrier (BBB) 
(András et al., 2003). Disruption of brain microvascular endothelial cells can 
activate platelets, promote thrombogenesis, and trigger cerebrovascular 
events (Yu et al., 2015). 
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Table 2.3.  Biomarkers & proposed mechanisms of Tat-induced upregulation 
 






• Pyrogenic & pro-inflammatory  
• Proliferation & differentiation of immune cells  
• Induction of MAPKs and NF-kB (MAPKs 
phosphorylate and activate transcription factors for 
pro-inflammatory genes) and NF-kB (Turner et al., 
2014) 
• Transcription of pro-inflammatory cytokines TNF-a, 
IL-6 & neutrophil recruiting chemokines 
• Increases BBB permeability &  leukocyte invasion 
(Yang, Wu & Lu, 2010) 
• Induces IL-1b independently of TNF-a, likely via NFkB (Nath et al., 
1999) 
• Phospholipase C (PLC) / protein kinase C (PKC)-dependent regulation 




• Macrophage chemotaxis across vascular 
endothelium (Weiss et al., 1999) 
• Activation of pro-atherogenic CD16+ monocytes 
(Parihar, Eubank & Doseff, 2010; Baker et al., 2014) 
• Likely via NFkB and Activator protein-1 (AP1) /MAPK pathway (Weiss et 
al., 1999; Toborek et al., 2002) 
• Initiates activation of the MAPK pathway and tyrosine kinase, stimulating 










• Principal endothelium-derived contracting factor 
(Virdis, Ghiadoni & Taddei, 2010) 
• Potent vasoconstrictor (National Center for 
Biotechnology Information, 2017a)  
• ETA receptor inhibition improves endothelial 
dysfunction and reduces atheroma formation (Barton 




• Regulates transcription of ET-1 via activation of NF-kB-responsive sites 
in ET-1 promoter (Chauhan et al., 2007) 
 
IL-6 
• Synthesis of acute phase proteins in liver 
• Leucocyte trafficking 
• T-cell activation, B-cell differentiation & antibody 
production (Turner et al., 2014) 
• NFkB and/or MAPK pathway (Nookala & Kumar, 2014; Ben Haij et al., 
2015) 
• Basic region of Tat needed for interaction with IL-6 promotor region 






• Inhibits cytokine production & mono-nuclear cell 
function 
• Anti-inflammatory (Turner et al., 2014)  
 
• Tat induces IL-10, which is regulated by CREB-1 and specificity protein 
1 (Sp-1) transcription factors, through the activation of MAPK (Gee et 
al., 2012) 
• Tat induces IL-1o via NF-kB, but activates NF-kB via two pathways: 
MAPK and PKC-dependent, involving CREB (Leghmari, Bennasser & 
Bahraoui, 2008) 






• Stimulates innate immune system: cytokine 
production, expression of adhesion molecules, 
phagocyte activation (Turner et al., 2014) 
 
• N-terminal domain 1-55 essential for TNF-a production  





• Increases vascular permeability  
• Angiogenesis  
• Chemoattractant (National Center for Biotechnology 
Information, 2017b) 
• Interacts with VEGF receptors (Avraham et al., 2004) 
• Induces VEGF in PMNLs via chemoattractant region (Benelli et al, 2000)  
 
E-selectin 
• Leucocyte migration, tethering & rolling  
• Leucocyte cell-cell adhesion  
• Heterophilic cell-cell adhesion (National Center for 
Biotechnology Information, 2017c) 
• NF-kB dependent mechanism via basic domain (Dhawan et al., 1997; 




• Leukocyte-endothelial cell adhesion & signal 
transduction  
• May play role in atherosclerosis development 
(National Center for Biotechnology Information, 
2017d) 
 




• Integrin binding  
• Leucocyte migration & adhesion  
• May be involved in atherosclerosis (National Center 
for Biotechnology Information, 2017e) 
• NFkB-promoter and MAPK (Dhawan et al., 1997; Duan et al., 2013) 
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2.6.5 The Tat protein in the central nervous system   
 
2.6.5.1 Entry of HIV into the CNS 
 
HIV enters the CNS early in the course of infection, as a result of migration of 
infected monocytes and lymphocytes across the blood brain barrier. The brain 
then becomes a significant reservoir for the virus. Subsequent infection of 
neighbouring cells, predominantly perivascular macrophages and microglia, 
results in viral replication in the CNS (Bissel & Wiley, 2004; Yadav & Collman, 
2009).  
 
2.6.5.2 CNS escape  
 
The sequestration of HIV-infected cells in the CNS is an important step in HIV-
related morbidity. CNS inflammation and CSF viraemia can persist in 
individuals with a suppressed peripheral viral load. This phenomenon of “CNS 
escape” (Yilmaz et al., 2008; Canestri et al., 2010; Peluso et al., 2012), means 
that CNS viral replication, and hence viral protein production, may continue in 
individuals on effective antiretroviral therapy, who have suppressed peripheral 
viral loads.  
 
2.6.5.3 Secretion of the Tat protein in the CNS  
 
The secretion of Tat from infected CNS cells may not be suppressed by current 
antiretroviral therapy. The presence of ART does not eliminate Tat secretion 
(Mediouni et al., 2012; Bachani et al., 2013; Mousseau, Mediouni & Valente, 
2015), and Tat is present in the brain and CSF of individuals with undetectable 
peripheral blood HIV-1 RNA (Johnson et al., 2013). Furthermore, the Tat 
protein may still be present in the CNS of an estimated 30-40% of patients in 
whom viral replication is suppressed in the CSF (Johnson & Nath, 2014). This 
may be explained by the fact that transcription or translation of some of the 
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regulatory and accessory genes, such as tat, can still take place in cells with 
non-productive infection (Bissel & Wiley, 2004). Concentrations of Tat needed 
to promote extra-cellular or non-transcriptional effects are much lower than 
those needed to transactivate the virus (Ensoli et al., 1993). The bystander 
effects of the Tat protein may therefore only need cellular hosts that are 
infected, but not necessarily producing new viral transcripts (Berman et al., 
2016).  
 
2.6.5.4 Tat-induced CNS IRIS  
 
The presence of Tat in the CNS, even at low concentrations, may also provoke 
ischaemia via a unique form of IRIS. Recovery of the immune system after the 
initiation of antiretroviral therapy often provokes an inflammatory reaction to 
foreign antigens, commonly those from opportunistic infections. Johnson and 
Nath postulate that a reconstituted immune system may also respond to 
residual HIV in the CNS, either acutely, or in patients who have been 
established on ART for several years. Specifically, it may be high 
concentrations of the Tat protein that stimulate an inflammatory response. This 
response has several CNS manifestations, including ischaemia (Johnson et 
al., 2013; Johnson & Nath, 2014).  
 
2.6.5.5 Risk to extra- and intra-cranial vessels   
 
The non-transcriptional effects of the Tat protein on vascular endothelium 
could theoretically occur wherever the Tat protein is secreted by infected cells. 
The Tat protein freely crosses the blood brain barrier (Banks, Robinson & 
Nath, 2005). It is therefore conceivable that the presence of Tat in intracranial 
vessels could be either due to Tat secreted by infected cells in peripheral 
blood, or release of Tat from infected cells in the CNS. If the Tat protein is 
persistently released from the CNS, independent of peripheral viral replication, 
then it is possible that intra- and extra-cranial vessels may be at particular risk 
of endothelial injury.  
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Thus, the Tat protein has the potential to contribute to vascular injury, and the 





Non-transcriptional effects of Tat  
Figure 2.5. Potential mechanisms by which the Tat protein could contribute to HIV-associated endothelial dysfunction  
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Oxidative stress 
Non-transcriptional effects of Tat 
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2.7 HIV-1 genetic variability in disease pathogenesis   
 
2.7.1 HIV-1 groups and subtypes  
HIV-1 is divided into four genetically distinct groups. Group M (major) is 
responsible for the current HIV pandemic, whereas Groups N to P are found 
in selected regions. HIV-1 Group M is comprised of nine different subtypes or 
clades, with multiple circulating recombinant forms (CRFs) (Hemelaar, 2012). 
HIV-1 is genetically highly diverse. There may be as much as 25-35% genetic 
variation between subtypes. Even within subtypes, viral isolates may exhibit 
up to 20% variation (Santoro & Perno, 2013).  
 
 
Subtype-C accounts for around 52% of all HIV infections worldwide, and 
predominates in sub-Saharan Africa (Ariën, Vanham & Arts, 2007). However, 
much of HIV-1 sequence research has historically been focused on HIV-1 
Subtype-B (see Figure 2.7), which is most prevalent in Europe and North 
America (Bagashev & Sawaya, 2013; Santoro & Perno, 2013).  
The pathogenesis of stroke in populations infected with the subtype that is 
specific to 52% of HIV-infected individuals needs further exploration, 
especially in a clinical, in vivo context.  
HIV-1  
Group M  Group N  Group O Group P  
A B C D F G H J K CRFs 
Groups  
Subtypes/Clades  




2.7.2 Viral mutation in HIV-associated disease 
Genetic variability and amino acid substitutions are considered to be an 
important mechanism for disease pathogenesis (Ng & Henikoff, 2006). 
Therefore, variation in the Tat protein may also attenuate or enhance its effects 
on vascular endothelium.  
2.7.2.1 Mechanisms of viral mutation  
The considerable genetic variation seen in HIV is partly due to a high 
replication rate, coupled with the notoriously error-prone reverse transcription 
enzyme. In addition, template-switching occurs between the two RNA strands 
Figure 2.7. Global distribution of all HIV sequences obtained from research and uploaded to the 
HIV Sequence Database. The pie-chart reflects the large amount of research done on HIV-1 
Subtype B in comparison to other subtypes. Image available from www.hiv.lanl.gov 
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during reverse transcription. HIV-1 genetic mutations impact on disease 
progression, viral transmission and antiretroviral resistance patterns (Pant Pai, 
Shivkumar & Cajas, 2012; Santoro & Perno, 2013; Lloyd, Kent & Winnall, 
2014; Palm et al., 2014).  
 
Genetic variation is also influenced by selection pressure. Selection pressure 
for HIV-1 is determined by the environment in which the virus is present. 
Factors such as host-specific immunity and antiretroviral therapy will influence 
HIV’s ability to replicate. Changes in amino acids will therefore assist or hinder 
the viral protein’s ability to survive the environmental pressures imposed upon 
it. Variations in the amino acid sequence of a protein can be synonymous, 
meaning that they do not change the primary structure of a protein, or non-
synonymous, in that the substitution alters the primary structure, and 
potentially the function of the protein. If a non-synonymous mutation (dN) at a 
particular site does not really affect the function and fitness of a viral protein, 
then the rate of non-synonymous compared to synonymous substitutions (dS) 
remains fairly balanced (dS»dN), and selection is neutral. However, if a non-
synonymous substitution confers an evolutionary advantage, and improves 
viral fitness, then the rate of non-synonymous substitutions will increase 
relative to the rate of synonymous substitutions (dN>dS). This is the process 
of positive selection. Conversely, if the non-synonymous mutation is 
deleterious to viral function or fitness, then the rate of synonymous 
substitutions will exceed that of non-synonymous substitutions (dS>dN), 
indicating that negative selection is underway (Poon, Frost & Pond, n.d.).   
 
2.7.2.2 Viral protein mutation in disease pathogenesis   
Recent evidence suggests that sequence variations in HIV regulatory and 
accessory proteins may have a role to play in disease pathogenesis. 
Functional differences in regulatory or accessory proteins may also be 
subtype-specific. For example, the functional ability of Nef to downregulate 
CD4 and human leukocyte antigen (HLA) Class 1 receptors differs between 
subtypes A, B, C and D (Mann et al., 2013).  
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2.7.2.3 Viral protein mutation in HIV-associated neurocognitive disorders  
Research into HIV-associated neurocognitive disorders (HAND) has shown 
that genetic diversity and variable expression of HIV-1 proteins may cause 
injury to, and loss of, neural cells, leading to clinically detectable neurological 
disease. Dual infection with different HIV-1 strains, resulting in increased viral 
diversity, has been associated with HAND, and may impact on 
neuropathogenesis (Wagner et al., 2016). On autopsy, specific viral 
polymorphisms can distinguish people with and without HAND (Power et al., 
1994, 1998; Smit et al., 2001). Recent work on the HIV-1 viral protein R has 
shown that certain amino acids are associated with significant differences in 
neurocognitive performance in HIV-infected persons (Dampier et al., 2017). 
These findings in HAND suggest that viral diversity and sequence variations 
within HIV-1 proteins may influence disease risk.  
 
2.7.2.4 Variation of the HIV-1 Tat protein in disease pathogenesis   
 
The Tat protein itself is continually evolving, often due to host selection 
pressure (Allen et al., 2000). These multiple amino acid substitutions can be 
subtype-specific, and impact on functionality (Roy et al., 2015). The effect of 
Tat variants has been researched in different clinical contexts, but not in 
ischaemic stroke.  
 
Mutations may affect the Tat protein’s cytoplasmic concentration and release 
(Ensoli et al., 1993), as well as its neurotoxic and chemotactic properties in the 
CNS (Cowley et al., 2011). Functional differences also exist between subtypes. 
In one study, Subtype C (Tat-C) and Subtype-E (Tat-E) Tat proteins were more 
powerful transactivators, in comparison with Tat Subtype B (Tat-B) (Desfosses 
et al., 2005). Studies comparing Tat-B to a CRF showed that only Tat-B 
upregulated certain matrix metalloproteinases, as well as pro-inflammatory 
chemokines and components of complement (Woollard et al., 2014; 
Bhargavan & Kanmogne, 2017).. Tat-B is also thought to be more neurotoxic 
than Tat-C isolates from India (Mishra et al., 2008). 
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There is still much to be clarified around the pathogenic potential of variations 
within Tat-C, especially in Sub-Saharan Africa. Southern-African Subtype-C is 
thought to be more neuro-virulent and have the potential to cause greater 
chemotaxis and neurocognitive impairment than Subtype-C isolates in South-
East Asia, for example (Rao et al., 2013).  
 
Despite in vitro evidence that the Tat protein has pro-inflammatory properties, 
with the potential to disrupt vascular endothelium, most of the exploration into 
Tat variants has been in relation to HAND and neuronal apoptosis. It is yet to 
be clarified whether there are any signature amino acid variations that are 
associated with stroke, or upregulation of endothelial biomarkers. Thus, 
sequencing and describing the Tat protein in our cohort of South-African 
participants may provide key insights into the pathogenesis of HIV-associated 
stroke in Tat-C infected individuals, as well as contributing to the knowledge-
base for development of effective therapies to reduce the incidence of 
cerebrovascular disease in HIV.  
 
2.8 Summary of the rationale for the study on the Tat 
protein in stroke  
 
Ischaemic stroke and HIV contribute significantly to the disease burden in 
South Africa. HIV-infected individuals, treated and untreated, are at increased 
risk of ischaemic stroke compared to the HIV-uninfected population.  
 
The pathogenesis of ischaemic stroke involves occlusion of vessels supplying 
the brain, either via embolism or in-situ thrombus development. Thrombotic 
vessel occlusion may occur when endothelial dysfunction reaches a critical 
threshold. Although the cause of ischaemic stroke in HIV is multifactorial, HIV 
itself is an independent risk factor, and the severity of HIV disease is positively 
correlated with endothelial dysfunction, a pro-thrombotic state, and stroke risk. 




Causes of stroke in HIV include opportunistic infections, cardio-embolism, 
coagulopathy and HIV-associated vasculopathy, which is thought to be a result 
of HIV-induced endothelial dysfunction.   
 
Viral particles and proteins, infected monocytes and leucocytes, cytokine 
upregulation and immune reconstitution inflammatory syndrome are all 
postulated to contribute to the inflammation that drives HIV-associated 
endothelial dysfunction.  
 
The HIV-1 Tat protein has numerous extracellular effects which could damage 
vascular endothelium. Secretion of the Tat protein can occur independently of 
viral replication and in the presence of antiretrovirals. Additionally, its paracrine 
effects occur at lower concentrations than those needed to transactivate the 
virus. These properties make it an ideal candidate for promoting HIV-
associated endothelial dysfunction and stroke in both treated and ART-naïve 
individuals. Furthermore, amino acid variations in the Tat protein may influence 
disease progression and pathogenesis. Although the apoptotic properties of 
Tat have been explored in relation to HAND, there is a need for exploration 
into the pro-inflammatory and chemoattractant properties of Tat in the context 
of ischaemic stroke.  
 
The Tat protein is one of multiple factors that may contribute to progression of 
endothelial dysfunction in HIV. The description of its genetic attributes and its 
effect on biomarkers of inflammation and endothelial dysfunction could further 











CHAPTER THREE: PLANNING THE RESEARCH  
 
3.1 Research question  
 
Do variations in the HIV-1 Tat protein have a role in HIV-associated 
endothelial dysfunction and stroke? 
3.2 Hypotheses 
 
3.2.1 There are significant differences in traditional cerebrovascular risk 
factors between young HIV-infected individuals with and without 
acute ischaemic stroke. Whilst HIV may be the single most 
important risk factor for stroke in individuals <45 years, traditional 
cerebrovascular risk factors may have a synergistic effect on 
stroke risk in HIV-infected individuals.  
3.2.2 Recent CD4 count, CD4 nadir and viral load are significantly 
different between young HIV-infected individuals with acute 
ischaemic stroke, and those without acute ischaemic stroke. Low 
CD4 count and elevated viral load are indicators of 
immunocompromise, immune dysregulation and increased viral 
replication. These factors increase inflammation and therefore 
could influence endothelial dysfunction.  
3.2.3 There are differences in Tat protein sequences between HIV-
infected individuals with acute ischaemic stroke and non-stroke 
controls.  
3.2.4 There are differences in Tat protein sequences between 
individuals with strokes due to HIV-associated vasculopathy and 
strokes due to alternative mechanisms. 
3.2.5 Certain positions and amino acids in the Tat protein are specifically 




3.3 Aims and objectives  
 
3.3.1 To compare the baseline demographic characteristics, 
cardiovascular risk factors and HIV-related factors between an HIV-
infected young stroke group and HIV-infected non-stroke controls.  
 
3.3.2 To describe the characteristics of acute ischaemic stroke in young 
HIV-infected individuals, in order to better understand the 
pathogenesis of young stroke in a South African population infected 
with HIV-1 Subtype C.  
3.3.2.1 To describe the clinical phenotype, severity and 
aetiology of acute ischaemic stroke in young South 
African HIV-1 Subtype-C infected individuals  
3.3.2.2 To separate the stroke group into two sub-groups: 
individuals with strokes due to HIV-associated 
vasculopathy, and individuals with strokes due to 
alternative mechanisms 
3.3.2.3 To compare the CD4 count, treatment status and viral 
load between the sub-groups of individuals with acute 
ischaemic stroke   
 
3.3.3 To describe and compare the amino acid composition of Subtype-C 
Tat exon 1 sequences between HIV-infected individuals with acute 
ischaemic stroke, and HIV-infected individuals without stroke.  
3.3.3.1 To sequence the HIV-1 Tat exon 1 in HIV-infected 
individuals with and without stroke  
3.3.3.2 To visualise and compare amino acid composition and 
variability between the stroke and control groups  
3.3.3.3 To identify signature sites in the amino acid 
alignments that are distinctly representative of the 
stroke group relative to the control group 
3.3.3.4 To investigate selection pressure on the stroke and 
control groups  
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3.3.4 To describe and compare the amino acid composition of HIV-1 
Subtype-C Tat exon 1 sequences in HIV-infected individuals with 
strokes of differing aetiology  
3.3.4.1 To separate the stroke group Tat protein sequences 
into two sub-groups: sequences representing strokes 
due to HIV-associated vasculopathy, and sequences 
representing strokes due to alternative mechanisms 
3.3.4.2 To visualise and compare amino acid composition and 
variability between the strokes of differing aetiology  
3.3.4.3 To identify signature amino acid differences between 
the two groups    
 
3.3.5 To determine whether the signature residues from Tat exon 1 
detected in this cohort are associated with markers of inflammation 
and endothelial dysfunction. These markers are: IL-1b, IL-6, IL-10, 
TNF-a, MCP-1, VEGF, endothelin-1, E-selectin, ICAM-1 and 

















CHAPTER FOUR: METHODOLOGY  
 
4.1 Introduction to methodology used in this study   
 
This chapter describes the study design, sample size and study participants. I 
describe the study setting, recruitment of participants, modified inclusion and 
exclusion criteria, and final sample size obtained for the project. I describe the 
published case definitions used to classify stroke aetiology in the HIV-infected 
stroke group. I then explain the laboratory methods I used to sequence the tat 
exon 1: proviral DNA extraction, polymerase chain reaction (PCR), and Sanger 
sequencing. Details are provided about the bioinformatics software tools I used 
to sequence and analyse the tat exon 1 from the cohort’s blood samples. This 
chapter also details the conventional statistical methods used to compare 
baseline characteristics between the groups, analyse the significance of the 
signature pattern analyses, and correlate the endothelial biomarkers with 
specific residues in tat exon 1.  
 
4.2 Study design  
 
This was a case-control study of individuals who were originally prospectively 
recruited for a larger study on HIV infection and stroke.  
 
4.3 Study participants 
 
This study was conducted as a sub-study of a larger research project entitled 
‘Stroke and HIV-infection: a study of markers of endothelial dysfunction and 
ultrasonographic vascular phenotypes’. This research, which commenced in 
2010, aimed to investigate the association between HIV and stroke in young 
adults. This study enrolled a cohort of HIV-infected individuals presenting with 
acute ischaemic stroke between the ages of 18 and 45 years, who were then 
characterized clinically, biochemically, and radiologically in order to determine, 
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as accurately as possible, their stroke aetiology and to investigate 
mechanisms by which HIV confers stroke risk. It also had two control groups: 
HIV-infected non-stroke controls and HIV-uninfected acute stroke patients, all 
between the ages of 18 to 45 years, who then underwent the same data 
collection process.   
4.3.1 Study setting  
The stroke group was recruited from a tertiary hospital and its affiliated 
secondary hospitals in Cape Town, South Africa. Groote Schuur Hospital is 
one of two central hospitals in the Western Cape province, and serves the 
central metropole, as well as the southern and some of the western sub-
districts. The HIV-infected non-stroke control group was recruited from two 
community health centres in Cape Town. Community health centres serve 
people in their local area. The two areas included Gugulethu, and Crossroads. 
 
The Cape Town metropole is the second most populous urban area in South 
Africa. When the study participants were enrolled, the city had with an 
estimated population of 3.7 million people. In 2011, the unemployment rate 
was 23.9%. Informal dwellings comprised 21.6% of all households (Statistics 
South Africa, 2011a). The HIV-1 prevalence in the Cape Town metropole was 
5.2% in 2012, and in 2011, HIV and cerebrovascular disease were the 
metropole’s 4th and 5th leading causes of natural death, respectively (Shisana 
et al., 2014; Statistics South Africa, 2014). 
4.3.2 Recruitment of the study cohort   
 
For the original study, HIV-infected and uninfected stroke patients were 
recruited from Groote Schuur Hospital in Cape Town and its affiliated 
secondary-level hospitals in the surrounding area. Recruitment and enrolment 
of the HIV-infected and uninfected stroke patients took place between 1st 
August 2010 and 30th June 2013. These were individuals between the ages of 
18 and 45 years, who presented with acute ischaemic stroke to the Stroke 
Service at Groote Schuur Hospital. Participants were enrolled at Groote 
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Schuur Hospital during the patient’s admission, within 5 to 7 days of stroke 
onset. HIV-infected individuals without acute stroke were recruited as controls 
during the same time period from two community health centres in the Cape 
Town area. As far as possible the controls were matched for age, sex, and 
antiretroviral status (treated or untreated). Written informed consent was 
obtained from all participants, or their closest relative, if cognition or level of 
consciousness were impaired. The consent form for the original study, in 
English and isiXhosa, can be found in Appendix B.  
 
To minimize the influence of conventional age-associated risk factors for 
stroke, the participants were all between 18 and 45 years of age.  
 
4.3.3 Inclusion and exclusion criteria for this sub-study 
This sub-study includes two of the three original groups: the HIV-infected 
stroke group, and HIV-infected non-stroke controls. Inclusion and exclusion 
criteria for these two groups were modified for the purpose of this study.  
 
Table 4.1. Modified inclusion and exclusion criteria 
 
  
Modified Inclusion Criteria 
 






• Age >18 years and <45 years 
• Ischaemic Stroke 
• Available blood specimens for 
laboratory analysis*  
• Written consent obtained 
 
• HIV-uninfected 
• Age <18 years or >45 years 
• Haemorrhagic stroke, 





• HIV-infected  
• Age > 18 years and <45 years  
• Available blood specimens for 
laboratory analysis*  
• Written consent obtained  
 
 
*Additional criteria for the purpose of this study 
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Of the original 63 HIV-infected young strokes, 62 met the above criteria. All 99 
of the original HIV-infected control group met the criteria for inclusion in this 
study.   





4.4 Specimens and imaging  
 
4.4.1 Blood tests and imaging performed between 2010 and 2013   
 
All participants had 30 millilitres of whole blood taken on enrolment into the 
original study. For the stroke participants, blood samples were taken within the 
first five days of stroke onset. The samples were separated into serum, 
Ethylenediaminetetraacetic acid (EDTA) plasma and buffy coats and stored at 
-80°C. Initial blood tests included chemistry, haematology, coagulation tests 
and serology. Biomarkers of endothelial activation and inflammation were 
performed with cytokine assays. These included IL-1b, IL-6, IL-10, TNF-a, 
MCP-1, VEGF, Endothelin-1, E-selectin, ICAM-1 and VCAM-1.  
Stroke and HIV infection:  
A study of markers of endothelial dysfunction and ultrasonographic vascular phenotypes  
HIV-uninfected 
Age 18-45 








No acute stroke 
 
HIV-infected 
strokes   
n=63 
HIV-uninfected 






strokes   
n=62 
HIV-infected non-





 (no blood samples) 
specimens) 
Figure 4.1. Attainment of final sample size for the study on the Tat protein  
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54/58 (93.1%) individuals in the stroke group and 3/71 (4.2%) of the controls 
had CSF taken by lumbar puncture for analysis. Tests done on CSF included 
cell count, chemistry, microscopy, tuberculous and fungal culture, cryptococcal 
latex antigen test (CLAT), India Ink stain, and a viral panel screen: varicella 
zoster virus (VZV), herpes simplex virus type 1 (HSV-1), herpes simplex virus 
type 2 (HSV-2), Epstein-Barr virus (EBV) and cytomegalovirus (CMV). VZV 
screening was done via polymerase chain reaction (PCR), as VZV-
Immunoglobulin G (Ig-G) testing was unavailable. Laboratory technicians 
analysing blood and CSF samples were blinded to whether the sample was 
from the stroke or control group. 48/58 (82.8%) of individuals with stroke and 
49/71 (69%) of controls had duplex Doppler imaging of the carotid arteries to 
determine the intima-media thickness. All of the stroke subjects had 
computerized tomography and/or magnetic resonance imaging of the brain, as 
well as electrocardiogram, echocardiogram, bubble studies or cardiac 
magnetic resonance imaging to determine stroke aetiology. Angiography of 
cerebral vessels was also performed if clinically indicated.  
 
4.4.2 Analysis of the Tat protein performed in this study     
I used the stored EDTA buffy coats for the DNA procurement, PCR and Sanger 
sequencing of the Tat protein in this study.  
 
4.5 Classification of stroke aetiology  
 
The aetiology of HIV-associated strokes is complex, and the classification is 
therefore not straightforward. The categories defined by the traditional Trial of 
Org 10172 in Acute Stroke Treatment (TOAST) classification (Adams et al., 
1993) may not adequately cover the multiple causes commonly seen in HIV 
infection. A 2016 consensus paper has classified the different causes of HIV-
associated stroke, in order to clarify and standardize definitions of stroke 
aetiology for future research into ischaemic stroke in HIV-infected individuals. 
The published algorithm uses a prescribed battery of tests and assists 
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researchers in determining the aetiology of HIV-associated ischaemic stroke. 
The main causes include opportunistic infection, cardio-thromboembolism, 
vasculitis, accelerated atherosclerotic vasculopathy, non-atherosclerotic 
vasculopathy, coagulopathy and small vessel disease. Ischaemic strokes 
which do not fit into any of the above categories may either have evidence of 
multiple aetiologies, or are classified as cryptogenic stroke (Benjamin, Bryer, 
et al., 2016). This algorithm was used to determine the aetiology for all stroke 
cases in this study (see Appendix C).  
 
4.6 Comparison of clinical characteristics 
 
4.6.1 Summary of statistical analyses performed in this study    
Statistical analysis was performed on the clinical data for the cohort using 
Stataâ (StataCorp LLC, Texas, USA). The shape of data distributions was 
evaluated with Kernel Density Plots. Continuous measurements were reported 
with mean and standard deviation, where the data were normally distributed, 
and comparisons between the groups were done with a two-sample t-test with 
unequal variances. Where the data were obviously skewed on Kernel Density 
Plot, continuous variables were reported with median and interquartile range 
(IQR), and comparisons were made with the two-sample Wilcoxon rank-sum 
(Mann-Whitney) test. Counts (No.), and percentages (%), were used for 
nominal variables, and compared using the Pearson Chi-square test of 
Independence or Fisher’s exact test, where appropriate. An alpha value of 0.05 
was used as the cut-off for significance in the analyses. A binary logistic 
regression model was fitted to evaluate carotid intima-media thickness, 
controlling for age and waist circumference. Pair-wise deletion was used to 
handle missing data for certain clinical and laboratory variables, and the valid 
percentages for nominal variables reported. Where there was a large number 
of missing values, the actual number of values analysed was reported in the 
results tables (see Chapter 5, Tables 5.1-5.4). Graphs were constructed using 
Microsoft Excel and GraphPad Prism 7.0c. Bioinformatic analysis of the Tat 
protein was done once the sequences were obtained (see section 4.8). 
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4.6.2 A note on the use of p-values   
There has been much debate in recent years about the use of a p-value to 
determine the meaning of a single result (Goodman, 1999). A recent guide on 
interpretation of the results of statistical tests acknowledged that any 
conclusion drawn about the likelihood of a hypothesis being true or not, cannot 
rely solely on statistical methods (Greenland et al., 2016). The results from the 
statistical tests that I performed in this study were part of a variety of 
considerations taken into account. Where possible, inferences I made about 
the clinical and scientific significance of my findings were not based on a single 























Sequencing of tat exon 1   
4.6.3 Summary of sequencing methods  
Proviral DNA was extracted from the stored peripheral blood samples of the 
study participants. We then performed pre-nested and nested polymerase 
chain reactions to isolate the tat exon 1 fragment. The PCR product for each 
participant was then sequenced with Sanger sequencing.  
 
Table 4.2. Kits and chemical products used for sequencing    
 
Product or Kit Manufacturer  
Machery-Nagel NucleoSpinâ Blood Kit Machery-Nagel GmbH & Co. KG, Düren, 
Germany 
Nuclease Free Water Promega, Madison, Wisconsin (WI), 
United States of America (USA)] 
GoTaqâ Flexi DNA Polymerase Promega, Madison, WI, USA 
5X Colorless GoTaq® Flexi Buffer Promega, Madison, WI, USA 
Magnesium Chloride Solution, 25mM Promega, Madison, WI, USA 
Deoxynucleotide Triphosphates (dNTPs) Promega, Madison, WI, USA 
SeaKemâ LE Agarose Whitehead Scientific (Pty) Ltd, Cape 
Town, SA 
Tris Acetate EDTA buffer Qiagen, Hilden, Germany 
GR Green Nucleic Acid Stain Inqaba Biotechnical Industries (Pty) Ltd, 
Pretoria, SA 
Promega 6 x Blue/Orange Loading Dye Promega, Madison, WI, USA 
Promega 1kb DNA ladder Promega, Madison, WI, USA 
Parafilmâ Bemis Company Inc., Neenah, WI, USA 
Macherey-Nagel Nucleospinâ Gel and PCR 
Clean-up Kit 
Machery-Nagel GmbH & Co. KG, Düren, 
Germany 
Applied Biosystems BigDye® Terminator 
v3.1 Cycle Sequencing Kit 
Applied Biosystems Inc., CA, USA 
Applied Biosystems BigDye® XTerminator
TM  
Purification Kit 






Table 4.3. Equipment used for sequencing 
 
Machine or Equipment Manufacturer 
Applied Biosystems Veriti™ 96 Well 
Thermal Cycler 
Applied Biosystems Inc., California (CA), 
USA] 
Applied Biosystems® GeneAmp® PCR 
System 9700  
Applied Biosystems Inc., CA, USA 
UVIprochemi II D-77 LS-26M gel 
documentation system  
UVitech, Cambridge, UK 
Nanodrop
TM 
ND 1000  NanoDrop Products, Delaware (DE), USA 
Applied Biosystems 3130xl Genetic 
Analyzer  
Applied Biosystems Inc., CA, USA 
 
4.6.4 Proviral DNA extractions   
 
DNA was isolated from 200μl of prepared buffy coat using the Macherey-Nagel 
NucleoSpinâ Blood Kit for extraction of genomic DNA from blood.  
The kit protocol (Macherey-Nagel, 2016) was followed and proviral DNA was 
eluted in 100 microlitres (μl) of pre-heated buffer solution. The DNA 
concentration of the samples was then checked with the NanoDrop
 TM
 ND 1000 
Spectrophotometer to ensure that the eluted DNA concentration would be 
adequate for downstream reactions.   
 
4.6.5 Polymerase chain reaction   
 
For the PCR, the Promega GoTaqâ Flexi Kit was used, according to 
manufacturer’s instructions (Promega Corporation, 2013). We elected to 
amplify vpr (HXB2 5559-5850) and tat exon 1 (HXB2 5831-6045) as a single 
fragment. The vpr gene lies in close proximity to, and slightly overlaps, tat exon 
1. Due to the availability of primers, and to simplify the PCR process, we 
initially elected to amplify the two genes as a single piece, to be separated 
after sequencing.  
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The Applied Biosystems Veritiä 96 Well Thermal Cycler and the Applied 
Biosystems GeneAmp® PCR System 9700 were used for the PCR, according 
to the user guides (Applied Biosystems, 2008, 2010a).  
 
The primers and protocol used are summarized below. 
 
4.6.5.1 Primers and protocol for PCR of tat exon 1 and vpr 
 
Table 4.4.  Primers used for pre-nested PCR of tat exon 1 & vpr  
 












5’-GTACCCCATAATAGACTGTGACC-3’ 64 6329←6351 
Expected 
Size  
1451 base pairs  
 
 
Table 4.5. Cycling conditions for pre-nested PCR of tat exon 1 & vpr 
 
Step Cycles Temperature (°C) Time 
Initial Denaturation 1 94 2 min 
Denaturation  
40 
94 30 sec 
Annealing 60 30 sec 
Elongation 68 2 min 
Final Elongation 1 68 10 min 





Table 4.6. Primers used for nested PCR of tat exon 1 & vpr 
 














5’-CTCATTGCCACTGTCTTCTGC-3’ 64 6209←6229 
Expected 
Size 
953 base pairs 
 
 
Table 4.7. Cycling conditions for nested PCR of tat exon 1 & vpr 
 
Step Cycles Temperature (°C) Time 




94 30 sec 
Annealing 60 30 sec 
Elongation 68 1 min 
Final Elongation 1 68 10 min 















Figure 4.2. Approximate locations of the pre-nested & nested PCR fragments for tat exon 1 
& vpr. Adapted from HIV Genome Map (www.hiv.lanl.gov) 
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There were 15 samples which did not amplify using the vpr and tat primers. 
These samples underwent a repeat PCR with alternative primers that were 
specific for the tat exon 1 region only. The primers and protocol used are 
summarized below.  
 
4.6.5.2 Primers and protocol for PCR of tat exon 1 only  
 
Table 4.8. Primers used for pre-nested PCR of tat exon 1 
 
















712 base pairs 
 
Table 4.9. Cycling conditions for pre-nested PCR of tat exon 1 
 
Step Cycles Temperature (°C) Time 
Initial Denaturation 1 94 2 min 
Denaturation  
40 
94 30 sec 
Annealing 55 30 sec 
Elongation 68 1 min 
Final Elongation 1 68 10 min 









Table 4.10. Primers used for hemi-nested PCR of tat exon 1 
 
















451 base pairs 
 
Table 4.11. Cycling conditions for hemi-nested PCR of tat exon 1 
 
Step Cycles Temperature (°C) Time 
Initial Denaturation 1 94 2 min 
Denaturation  
40 
94 30 sec 
Annealing 55 30 sec 
Elongation 68 1 min 
Final Elongation 1 68 10 min 














Figure 4.3. Approximate locations of the pre-nested & hemi-nested PCR fragments for 
tat exon 1. Adapted from the HIV Genome Map (www.hiv.lanl.gov)  
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4.6.6  Gel electrophoresis and visualisation  
 
The gene fragments were separated by 0.8% agarose gel electrophoresis. The 
agarose gels were prepared with agarose powder and 1 x Tris-Acetate-EDTA 
(TAE) buffer. GR Green Nucleic Acid Stain was added to the agarose gel 
solution at a ratio of 1μl:10ml. The samples were loaded with Promega 6 x 
Blue/Orange Loading Dye. Promega 1kb DNA ladder was used as a marker. 
Each gel contained one negative control. The electrophoresis was run at 80V 
and 400mA for 35 minutes.  
 
The UVIprochemi II D-77 LS-26M gel documentation system was used for 
fluorescence and image acquisition of the proviral DNA fragments.  
 
 
Figure 4.4. An example of an image acquired after gel electrophoresis and fluorescence 
4.6.7 PCR purification 
The PCR purifications were performed with the NucleospinÒ Gel and PCR 
Clean-up kit, according to manufacturer instructions (Machery-Nagel, 2017).  
The DNA concentration of the purified PCR products was then measured with 





4.6.8 DNA Sanger sequencing  
Whilst there is an enormous biodiversity of HIV-1 within individuals, a number 
of dominant sequence clusters exist (Yin et al., 2012). The predominant 
sequence is determined by selection pressures such as antiretroviral therapy, 
host immune response and environmental factors (Dampier et al., 2016). 
Sanger sequencing identifies the consensus sequence, and will not detect 
minor variants in an individual (Dampier et al., 2017).  
 
The sequencing of the purified PCR products was done using the Applied 
Biosystems BigDye® Terminator v3.1 Cycle Sequencing Kit, according to the 
user guide (ThermoFisher Scientific, 2016). The DNA was diluted to a 
concentration of 15-25 ng/µl. The primers, master mixes and cycling conditions 
used are detailed in the tables below.  
 
Table 4.12. Primers for cycle sequencing of tat exon 1 & vpr 
 
Table 4.13. Primers for cycle sequencing of tat exon 1 
 
 
Table 4.14. Master mix for sequencing reactions 
Reagent 1X (µL) 
Nuclease Free Water 4.5 
5 x Reaction Buffer 3 
XTerminator Reaction Mix 0.5 
Primer (5pM/µL) 1 
Total aliquot 9 
DNA Sample (15-25ng/µL) 1 
 


























Table 4.15. Conditions for cycle sequencing of tat exon 1 & vpr 
 
 Temperature Time Number of Cycles 
Denaturation 96° C 10 seconds  
25 Annealing 58° C 5 seconds 
Extension 60° C 5 minutes 
 
Table 4.16 Conditions for cycle sequencing of tat exon 1 
 
 Temperature Time Number of Cycles 
Denaturation 96° C 10 seconds  
25 Annealing 55° C 5 seconds 
Extension 60° C 4 minutes 
 
After cycle sequencing, the fragments were then purified with the BigDye® 
XTerminatorTM Purification Kit, according to the manufacturer’s protocol 
(Applied Biosystems, 2007).  
 
Table 4.17. Master mix for purification of cycle sequencing products 
 
Reagent 1X (µL) 
SAMä Solution 4.5 
XTerminatorä Solution 0.5 
Total aliquot 55 (µL 
 
The sequences were then converted into raw data files with the Applied 
Biosystems 3130xl Genetic Analyzer, according to the user guide (Applied 
Biosystems, 2010b). Of the cohort of 161 participants, we obtained 58/62 and 
76/99 readable nucleotide sequences for the stroke and control groups 
respectively. We used these for further analysis.   
 
 
HIV-infected strokes   
n=62 
HIV-infected controls   
n=99 
HIV-infected strokes   
n=58 
HIV-infected controls  
n=76 
4 excluded (unreadable 
sequences) 
 
23 excluded (unreadable 
sequences) 
 
Figure 4.5. Number of nucleotide sequences suitable for further analysis  
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4.7 Sequence analysis  
 
4.7.1 Introduction to bioinformatics for sequence analysis  
I used bioinformatics software tools to organise and analyse the sequences. I 
converted the raw data files into fasta format, which is the file type used by 
most software for sequence analysis. The nucleotide sequences were 
translated into amino acid sequences and I separated the cohort into stroke 
and control groups. The sequences underwent quality control assessment and 
subtyping. 5/76 (6.6%) of the control sequences were excluded after 
subtyping, to create a cohort that was composed entirely of Subtype-C 
sequences. This was to minimise the influence of greater genetic variability 
seen between subtypes. I then created consensus sequences for the groups, 
visualised dataset similarity between groups, and performed signature pattern 
analysis. Additionally, I looked for evidence of positive selection pressure in 
the stroke and control groups.  
 
Table 4.18. Bioinformatics software used for sequence analysis 
 





• Consensus sequence 
generation 
• Weblogo generation 
• Calculates frequency by 
position & finds variants 




www.qiagenbioinformatics.com • Sequence visualization, 
editing and analysis 
• Sequence alignment 
Consensus 
Maker 
www.hiv.lanl.gov • Consensus sequence 
generation 






• Quantifies uncertainty in a 
dataset 
• Consensus sequence 
generation 
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Geneious R11 www.geneious.com 
(Biomatters Limited, 2017) 





www.hivmut.org (Davey et al., 2014) 
Collaboration between Briggs Group 
(European Molecular Biology 
Laboratory, Heidelberg) and 
Schneider Group (Luxembourg 
Centre for Systems Biomedicine, 
Luxembourg) 
• HIV-1 mutation data from all 





(Zhang et al., 2006) 
• Subtyping and detection of 






• Database of HIV genetic 
sequences 
• Access to tools to analyse 
and visualize data 






Stanford University HIV Drug 
Resistance Database(De Oliveira et 
al., 2014) 
• Determination of HIV-1 
subtype 





(Gene Codes Corporation, 2014) 
• DNA Sequence Analysis 
and contig assembly 
Shannon 
Entropy Two  
 • Determination of site-
specific variability  
Quality Control www.hiv.lanl.gov • Prepares sequences for 
submission to GenBank 
• Subtyping 
• Finds similar database 
sequence 
• Constructs phylogenetic 
trees 
• Detection of number of stop 
codons and frameshifts 








ESPA/vespa.html (Korber & Myers, 
1992) 
• Signature patterns in query 
sequences relative to 
background sequences 
WebLogo www.weblogo.threeplusone.com 
(Crooks et al., 2004) 
• Sequence logo generation 
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4.7.2 Acquisition and preparation of final sequences for analysis  
 
The HXB2 reference sequence was downloaded from the Los Alamos National 
Laboratory (LANL) HIV Database. The HXB2 reference sequence is the most 
commonly used reference strain for functional studies. This internationally-
accepted reference sequence facilitates the uniform identification of a position 
number and precise location of interest in HIV-1 DNA or proteins (Korber et 
al., 1999). The HXB2 tat exon 1 was imported and used as the reference to 
assemble the sequence contigs in Sequencher version 5.2.4. (Gene Codes 
Corporation, 2014). Each Sequencher-generated contig was manually 
checked, then exported in fasta format into Geneious version R11 (Biomatters 
Limited, 2017). Of the 161 samples, I obtained 134 readable sequences.  
 
I created a multiple alignment of the entire cohort using Multiple Alignment 
using Fast Fourier Transform (MAFFT) within Geneious. The sequences were 
then codon-aligned and manually checked. One of the study cohort sequences 
(1/134; 0.75%) had a single amino acid insertion at position 52, resulting in a 
multiple alignment that was 73 amino acids in length. Most functional studies 
of amino acid substitutions and activities of various Tat domains have utilized 
the HXB2 reference sequence, which is 72 amino acid residues in length. 
Furthermore, analysis of the sequences required the use of the HIV Mutation 
Browser, which annotates proteins according to the HXB2 reference 
sequence. I therefore decided to gap-strip the sequence with the insertion, to 
obtain a 72-amino acid sequence alignment of the entire cohort. This allowed 
for analysis of mutations at positions which corresponded with the scientific 
literature on the Tat protein. As there was only one sequence with an insertion, 
gap-stripping was unlikely to significantly compromise the validity of the results 
in this cohort.  
 
The sequences were then separated into stroke and control groups, and 
realigned. All nucleotide sequences were then translated into amino acids, 
realigned and manually re-checked to confirm the alignments.  
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4.7.3 Quality Control  
I performed sequence quality analysis on all sequences using the Quality 
Control Tool. This tool examines nucleotide sequences for common problems, 
and prepares sequence sets for submission to GenBank.   
4.7.4 Subtyping of the study cohort  
The study cohort was subtyped using the jumping profile Hidden Markov Model 
(Zhang et al., 2006). This was cross-checked with REGA HIV-1 Subtyping tool 
(De Oliveira et al., 2014). The results of the subtyping showed that 129/134 
(96.3%) of all study cohort sequences were Subtype-C, which is the 
predominant subtype both globally and in Sub-Saharan Africa. The other 
subtypes, all in the control group, were excluded from the subsequent 
analyses, as the significant genetic variation between subtypes could influence 
the amino acid signature patterns in this study. The excluded subtypes were 
A1 (n=3), B (n=1) and G (n=1).  
 
 
Figure 4.6. Example of subtyping results from the jumping profile Hidden Markov Model. 
The participant identified as YSH080 was Tat Subtype-C, and was included in the 




4.7.5 Consensus sequences 
Consensus sequences for the stroke and control groups were created with four 
separate online tools, in order to cross-check accuracy. Consensus 
sequences were created using the Advanced Consensus Maker, SeqPublish, 
AnalyzeAlign and Entropy tools, all four of which showed 100% agreement on 
the derived consensus for each group. The consensus sequences were used 
to visualize dataset similarity.  
4.7.6 Visualization of dataset similarity 
SeqPublish was used to identify similarity between the stroke and control 
datasets. SeqPublish is a sequence alignment publisher tool. It aligns a 
dataset to a consensus sequence and represents identical residues at each 
position with dashes. The stroke group sequences were aligned to the 
consensus sequence for the control group.  
 
 
Figure 4.7. Example of subtyping results from the jumping profile Hidden Markov Model. 
The participant identified as YSH076 was Tat Subtype-B, and was excluded from the 
analysis.   
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4.7.7 Visualization and analysis of site-specific variability 
The CLC Sequence Viewer (Qiagen Bioinformatics, 2017) was used to 
visualize the variability of amino acid residues at each position in relation to a 
consensus of the dataset. The software creates a consensus sequence for the 
cohort, then generates a histogram depicting the conservation of the 
consensus residue at each position.  
4.7.8 Signature pattern analysis 
Signature pattern analysis identifies positions in a sequence at which the most 
common amino acid differs between a query sequence alignment and a 
background sequence alignment. The comparison detects an amino acid 
signature that is unique to the query group. It detects amino acid substitutions 
that may be unique to the query group relative to the background group.   
 
Signature pattern analysis was done with Viral Epidemiology Signature Pattern 
Analysis (VESPA), which calculates the frequency of all amino acids for the 
query and background groups at each position in the alignments. It then 
selects the positions for which the most common character in the query group 
differs from the background group. The analysis highlights amino acids that 
characterize the unique differences between two groups of sequences. The 
specific amino acid signature is obtained by looking for the set of amino acids 
that is conserved within each group, but differs between the two groups 
(Korber & Myers, 1992). Signature pattern analysis purposefully uses the most 
common amino acid at a position, rather than merely describing positions that 
exhibit differences in amino acid distributions (Huang et al., 2012).   
 
The VESPA amino acid frequency calculations for all analyses were cross-
checked with AnalyzeAlign. There was 100% agreement in the frequency 
calculations across all groups between the two software tools.  
 
Signature pattern analysis was also performed for the stroke group, which was 
separated into two subgroups by aetiology.  
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It is important to note that 11 sequences in total (8 in the control group, and 3 
in the stroke group) were short, and did not reach the full 72 amino acid length 
on Sanger sequencing. These were included in the analysis, but I was aware 
that from position 31 onwards, at least 1 of the 11 short sequences had missing 
data, which may have affected signature pattern analysis.  
 
I used sequence logos to depict the signature amino acid differences between 
the groups. Sequence logos present an alternative visual overview of the 
sequence characteristics unique to each group. A sequence logo graphically 
represents the conservation of amino acids in a set of aligned sequences. The 
logo depicts the consensus sequence as well as amino acid diversity at each 
position. I created sequence logos for the regions around the signature amino 
acids detected by signature pattern analysis. The sequence logo for the Tat 
protein consists of a stack of single-letter amino acid abbreviations at each 
position on the x-axis. The height of the symbols on the y-axis represents the 
relative frequency of each amino acid at that position. Sequence logos were 
created using Weblogo 3.0. (Crooks et al., 2004) and cross-checked with 
AnalyzeAlign. 
4.7.9 Separation of the stroke group by stroke cause  
The participants in the stroke group had their stroke aetiology classified 
according to published case definitions (Benjamin et al., 2012; Benjamin, 
Bryer, et al., 2016). The first was those strokes due to HIV-associated 
vasculopathy. I included cryptogenic stroke in this group. Cryptogenic strokes 
are those strokes for which, after exhaustive investigations, no cause has been 
found. In these individuals, HIV infection itself is possibly the only major risk 
factor that remains. Cryptogenic stroke may represent undiagnosed HIV-
associated vasculopathy (Benjamin et al., 2012, 2017). The background group 
included all strokes that had a confirmed or probable cause that was not 
directly due to HIV-associated vasculopathy. Six patients were excluded from 





Table 4.19. Stroke sequences classified by aetiology 
 
Strokes due to HIV-associated 
vasculopathy (n=25) 
Strokes due to alternative 
mechanisms (n=27) 
• Non-atherosclerotic vasculopathy (n=14) 
• HIV-associated vasculitis (n=4) 
• Accelerated atherosclerotic vasculopathy (n=3) 
• Cryptogenic (n=3)  
• Small vessel disease without hypertension 
(n=1) 
• Opportunistic infections (n=13) 
• Cardioembolism (n=9) 
• Other determined cause (n=3) 
• Small vessel disease with hypertension 
(n=2)  
 
This separation of the strokes into two groups was to explore whether an 
amino acid signature pattern could be detected between the strokes with a 
confirmed or probable alternative cause, in relation to the strokes due to HIV-
associated vasculopathy. The paracrine effects of the Tat protein may result 
in the direct endothelial damage that is postulated to contribute to HIV-
associated vasculopathy. Amino acid mutations in the Tat protein could alter 
these paracrine effects. An attenuation or enhancement of the chronic 
persistent inflammatory process or viral replication may determine the extent 
of endothelial dysfunction directly caused by HIV versus endothelial 
dysfunction from other mechanisms.  
4.7.10 Signature amino acid mutation search 
The substitutions at the amino acid positions identified with signature pattern 
analysis were then explored with the HIV Mutation Browser. This database 
contains mutation data collated from all HIV-related scientific literature. The 
data are “identified and catalogued using computational text-mining methods” 
(Davey et al., 2014), and are frequently updated. The HIV Mutation Browser 
can be used to find literature describing the mutation phenotype, as well as 
any functional effect of the substitution. It has four options for data review. The 
feature view enables visualisation of the region in which the mutation resides, 
and its relationship with any important functional areas. The sequence view 
shows the amino acid sequence of the protein, and data for each residue can 
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be accessed by clicking on the residue of interest. The table view displays the 
most common amino acid at each position, as well as its conservation at that 
site, the secondary structure and number of known mutations at that position. 
The residue view displays links to scientific articles related to the residue, as 
well as a residue information panel which displays structural and conservation 
information (Davey et al., 2014).  
 
 




Figure 4.9. HIV Mutation Browser Feature View. www.hivmut.org 
 
 
4.7.11 Significance of signature pattern analyses 
Fisher’s exact test was used to determine the significance of the amino acid 
signature patterns identified by VESPA. P-values were determined for 
signature amino acids in the stroke group relative to the control group. P-
values were also determined for the signature pattern identified for the strokes 
that were separated by aetiology. A p-value of ≤0.05 was used to represent 




4.7.12 Determination of positive selection in the stroke and control 
groups 
I assessed positive selection via Datamonkey (http://classic.datamonkey.org), 
a selection analysis website that employs various selection pressure models 
to analyse selection pressure on a set of uploaded sequences.  
 
I used Single-Likelihood Ancestor Counting (SLAC) to analyse positive 
selection pressure in the cohort. SLAC is recommended for data sets with 
more than 40 sequences (Kosakovsky Pond & Frost, 2005) and has sufficient 
power to detect positive and negative pervasive selection. This model 
assumes that “selection pressure for each site is constant along the entire 
phylogeny” (HyPhy, 2017). SLAC is a conservative method, with a type 1 error 
rate less than the nominal p-value. The default significance level is therefore 
set at 0.1. “SLAC uses a combination of maximum-likelihood (ML) and 
counting approaches to infer nonsynonymous (dN) and synonymous (dS) 
substitution rates on a per-site basis for a given coding alignment and 
corresponding phylogeny” (HyPhy, 2017). I used the most general time-
reversible nucleotide substitution model (REV) to evaluate the phylogenetic 
tree of the alignment and estimate nucleotide substitution bias rates (Poon, 
Frost & Pond, n.d.).  
 
4.8 Correlation of signature positions with endothelial 
biomarkers  
 
4.8.1 Rationale for correlation of signature positions with biomarkers  
The scope of this project did not include cell-culture studies to assess the 
functional impact of the viral isolates in this cohort. I was nevertheless 
interested as to whether any of the signature positions identified had a 
correlation with the endothelial biomarkers measured in these individuals. I 
elected to do an experimental statistical analysis as a preliminary step, with 
the view that cell-culture studies can be done in future work. I decided to follow 
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the example of Dampier et al. (Dampier et al., 2017), who correlated specific 
amino acids in HIV-1 Vpr with neurocognitive status using statistical models.  
4.8.2 Model construction process  
I took a slightly different approach to that followed by Dampier et al., due to the 
fact that we were working with ten outcome variables (the biomarkers), rather 
than the two they used to look at neurocognitive status. I also wanted to avoid 
having to do Bonferroni adjustment, as it assumes a universal null hypothesis 
and may increase Type II error rates (Perneger, 1998).  
 
I chose to control for the effect of age, CD4 count, stroke or non-stroke and 
ART status (treated or untreated) on the biomarkers. I then introduced the 
three signature positions identified by VESPA into the models. At each 
position, I chose the most common amino acids for that position and coded 
them into categories. For position 21, proline was the indicator variable, with 
alanine and other amino acids as a reference category. At position 29, 
histidine, lysine and arginine were the indicator variables, with other amino 
acids as the reference category. At position 58, alanine was the indicator 
variable, with threonine as the reference category.  
 
Linear regression models were fitted for all 10 biomarkers and then the 
residual analysis plots were inspected to assess normality and variance for 
each model. On inspection, E-selectin had little deviation from normality, and 
displayed constant variance. VCAM-1, ICAM-1, VEGF, TNF-a, Endothelin-1 
and MCP-1 had slight deviation from normality, and were natural log 
transformed to stabilise variance.  
 
Many of the values for IL-1b, IL-6, and IL-10 were 0.00, and had serious 
deviation from normality with non-constant variance. IL-1b was excluded from 
analysis because only four values were above 0.00, and complete separation 
occurred with the stroke variable and position 29. IL-6 and IL-10 were treated 
as binary variables, and logistic regression models were fitted for these two 
biomarkers. On inspection of the standardised Pearson and deviance 
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residuals, no large values to indicate a poorly-fitting model were observed for 
IL-6 or IL-10.  
 
The significance level was set at 0.05, to evaluate whether the signature amino 
acids identified by VESPA had a positive or negative effect on the value of the 
biomarker in the cohort.  
 
Overall, the models were a reasonable fit, given that this was intended as a 
preliminary exploration of correlation of the signature positions with the 
biomarkers. Limitations included problems with non-constant variance with 
some of the biomarker models. There were also a few outliers on some of the 
models, mostly with CD4 count, and I anticipate that the models can be 
improved with regards to this variable. A non-linear relationship with CD4 count 
and endothelial biomarker activation was noted, which may be physiological. 
The models were re-run with the square-root of the CD4, but this did not make 




















CHAPTER FIVE: RESULTS  
 
5.1 Introduction to results  
 
In this chapter, I present the results of the analyses conducted on the case 
and control groups. Firstly, a comparison of the two groups at baseline is 
presented, looking at demographics, traditional cardiovascular risk factors, 
laboratory values and imaging as well as HIV-related factors. In the group with 
acute arterial ischaemic stroke, I describe in detail the overall profile of HIV-
associated stroke in this cohort. The clinical stroke phenotype, stroke severity 
and stroke aetiology are reported, in order to better understand the type of 
arterial ischaemic stroke commonly encountered in HIV-1 Subtype-C infected 
South African individuals, and the factors that contribute to the progression of 
endothelial dysfunction to ischaemic stroke.    
 
Thereafter the results of the sequence analysis are presented, looking at the 
consensus sequences of the two groups, visualisation of dataset similarity and 
















5.2 Demographics of the study cohort  








Mean age, years (SD) 33.0 (5.8) 33.3 (6.1) 0.7924 
Gender   0.239 
Male 22 (37.9) 20 (28.2) 
 
Female 36 (62.1) 51 (71.8) 
 
Ethnicity   0.007 
Black African 52 (89.7) 71 (100.0) 
 
Mixed Ancestry 6 (10.3) 0 
 
Caucasian/other  0 0 
 
Unemployed* 28 (49.1) 41 (60) 0.288 
Abbreviations: SD, standard deviation 
Values are depicted as No. (%), unless otherwise indicated 
*Missing data; pairwise deletion used in the analysis   
aP value was calculated for categorical variables using Fisher’s 2-sided exact test or Pearson’s Chi-square test. 
P-values for continuous variables were derived with the t-test or two-sample Wilcoxon rank-sum (Mann-Whitney) 
test.   
 
 
The two groups were similar with regards to age and gender, with a mean age 
of 33.0 years and 33.3 years in the stroke and control groups respectively, and 
a predominance of females (62.1%; 71.8%). The ethnicity profile was different 
between the two groups (p=0.007). The stroke group was comprised of 89.7% 
Black Africans, and 10.3% were individuals of Mixed Ancestry. The control 
group was comprised entirely of individuals of Black African ancestry. 
Unemployment, as a reflection of socioeconomic status, was similar between 

















5.3 Risk factor profile  
 







Hypertension 11 (19) 8 (11.3) 0.220 
Mean SBP, mmHg (SD) 120.8 (16.1) 120.4 (21.0) 0.9121 
Diabetes 4 (6.9) 0 (0.0) 0.039 
Mean waist circumference, cm (SD)  86.9 (13.2) 90.4 (15.7) 0.1895 
Dyslipidaemia 0 (0.0) 0 (0.0) 
 
Smoker* 17 (29.8) 21 (29.6) 0.976 
Median pack years (IQR) 7.0 (7.0) 2.5 (3.0) 0.0111 
Stratified pack yearsb 
  
0.004 
<5 pack years 5 (29.4) 18 (85.7) 
 
5-10 pack years 7 (41.2) 1 (4.8) 
 
>10 pack years 5 (29.4) 2 (9.5) 
 
Alcohol use* 16 (28.1) 32 (45.1) 0.048 
Median units/wk (IQR) 8.0 (24.0) 9.0 (17.5) 0.1695 
Substance use 4 (6.9) 3 (4.2) 0.700 
    
History of previous TIA 5 (8.6) 0 (0.0) 
 
History of previous stroke 3 (5.2) 1 (1.4) 0.3258 
Known cardiac disease 2 (3.4) 0 (0.0) 0.200 
History of recent infection <3mo 13 (22.4) 10 (14.1) 0.219 
Type of recent infectionc  
  
0.009 
Chickenpox/shingles 2 (15.4) 0 (0.0) 
 
Respiratory tract 7 (53.8) 2 (20) 
 
Tuberculosis 2 (15.4) 0 (0.0) 
 
Genital 0 5 (50) 
 
Unknown 2 (15.4) 3 (30) 
 
Chickenpox/shingles (<6mo) 7 (12.1) 3 (4.2) 0.112 
  
   
Enrolment during pregnancy/ 
puerperium 
1 (2.8) 0 (0.0) 
 
Oral contraception  1 (2.8) 2 (3.9) 
 
 
Abbreviations: cm, centimetres; mmHg, millimetres of mercury; mo, months; SBP, systolic blood pressure; SD, 
standard deviation; TIA, transient ischaemic attack; wk, week 
Values are depicted as No. (%), unless otherwise indicated.  
*Missing data; pairwise-deletion used in analysis  
aP value was calculated for categorical variables using Fisher’s 2-sided exact test or Pearson’s Chi-square test. P-
values for continuous variables were derived with the t-test or two-sample Wilcoxon rank-sum (Mann-Whitney) test.  
b Expressed as a No. (%) of those who were current smokers 




Of the known traditional risk factors for cardiovascular disease, there were no 
differences in hypertension (19% vs 11.3%), mean systolic blood pressure 
(120.8mmHg; 120.4mmHg), mean waist circumference (86.9cm vs 90.4cm), 
current smokers (29.8% vs 29.6%), substance use (6.9% vs 4.2%) or known 
cardiac disease (3.4% vs 0%) between the stroke and control groups. A waist 
circumference predictive of metabolic syndrome (Motala et al., 2011) was 
present in 38.7% of female and 28.6% of male stroke subjects, and in 49% of 
females and 30% of males in the control group.  
 
The stroke group had a higher prevalence of diabetes (6.9% vs 0.0%, p=0.039) 
and more pack-years of smoking in comparison to the controls (41.2% and 
29.4% of stroke subjects had a >5 and >10 pack-year history of smoking 
respectively, compared with 4.8% and 9.5% of controls, p=0.004). Alcohol use 
was more prominent in the control group, with 45.1% of controls reporting 
regular alcohol use, in comparison to 28.1% of the stroke group (p=0.048). 
Although 5.2% of the stroke group and 1.4% of the control group reported a 
previous stroke, this difference was not statistically significant.  
 
There was no difference in the number of participants reporting chicken pox or 































Figure 5.1. Comparison of traditional cardiovascular risk factors 
 
Abbreviations: HPT, hypertension  




4.2% of controls). However, the two groups reported different types of infection 
in the 3 months preceding enrolment (p=0.009). Of those who reported a 
recent infection, respiratory tract infection (53.8%), chicken pox or shingles 
(15.4%) and tuberculosis (15.4%) were more common in the stroke group, 
whilst genital infections (50%), unknown infections (30%) and respiratory tract 
infections (20%) predominated in the controls.  
 
 
































































5.4 Laboratory values and imaging   
 







Fasting lipogram* n=50 n=16  
Mean total cholesterol, mmol/L (SD) 4.15 (1.47) 3.18 (0.56) 0.0004 
Mean LDL, mmol/L (SD)   2.58 (1.39) 1.80 (0.53) 0.0045 
Mean Trigs, mmol/L (SD) 1.25 (0.56) 0.69 (0.34) 0.0001 
Mean HDL, mmol/L (SD) 0.98 (0.36) 1.01 (0.50) 0.7657 
Serum RPR/TPHA positive  4 (6.9) 0 (0.0) 0.034 
APLA screen positive 8 (13.8) 0 (0.0)  
Autoimmune vasculitis screen positive  4 (6.9) 0 (0.0)  
Carotid Intima-Media Thickness* n=48 n=49  
Mean CIMT, mm (SD) 0.50 (0.9) 0.56 (0.9) <0.001 
Cerebrospinal fluid analysis n=54 n=3  
Mean CSF polymorphs, cells/mm3 (SD) 0.81 (5.0) 0.0 (0.0)  
Mean CSF lymphocytes, cells/mm3 (SD) 23.4 (82.9) 17.7 (20.9)  
Mean CSF glucose, mmol/L  2.97 (0.5) 3.1 (0.4)  
Mean CSF protein, g/dL 0.49 (0.3) 0.55 (0.3)  
CSF FTA positive  4 (7.4) 0.0 (0.0)  
CSF VZV PCR positive 6 (11.1) 0.0 (0.0)  
Full Blood Count*    
Mean Hb, g/dL (SD)  11.7 (2.1) 12.4 (1.8) 0.0670 
Mean WCC, cell x 109/L (SD)  6.35 (3.39) 5.06 (1.62) 0.0117 
Mean Platelets, cells x 109/L (SD)  317.5 (128) 263.9 (82.5) 0.0085 
 
Abbreviations: APLA, antiphospholipid antibody; BP, blood pressure; CIMT, carotid intima-media thickness; CSF, 
cerebrospinal fluid; Hb, haemoglobin; HDL, high density lipoprotein; LDL, low density lipoprotein; RPR, rapid plasma 
reagin; TB, tuberculosis, TIA, transient ischaemic attack; Trigs, triglycerides; WCC, white cell count 
Values are depicted as No. (%), unless otherwise indicated.  
*Missing data: pairwise deletion used in analysis  
aP value was calculated for categorical variables using Fisher’s 2-sided exact test or Pearson’s Chi-square test. P-









Laboratory values and carotid duplex Doppler for assessment of 
cardiovascular risk differed between the two groups. Mean total cholesterol 
(4.15 mmol/l vs 3.18 mmol/l, p=0.0004), LDL (2.58 mmol/l vs 1.80 mmol/l, 
p=0.0045) and triglycerides (1.25 mmol/l vs 0.69 mmol/l, p=0.0001) were 
higher in the stroke group compared with the control group. 6.9% of the stroke 
group and none of the controls tested positive for syphilis (p=0.034). Screening 
for antiphospholipid antibody syndrome and vasculitis was positive in 13.8% 
and 6.9% of the stroke group respectively, whilst none of the control group had 
a positive screening test for these conditions. Mean carotid intima-media 
thickness was greater in the control group (0.56mm vs 0.50mm, p<0.001). 
When a binary logistic regression model was fitted to evaluate CIMT, 
controlled for age and waist circumference, results showed that for every unit 
increase in CIMT, the odds of stroke are expected to decrease by a factor of 
0.224 (77.6%; SE=0.085, p<0.001).  
 
Lumbar puncture was performed in 54/58 individuals in the stroke group, and 
3/71 individuals in the control group. 7.4% and 11.1% of the stroke group were 
positive for neurosyphilis and varicella zoster virus PCR, respectively. The 
small number of individuals in the control group precluded any meaningful 
comparisons between the CSF variables. There were differences in the white 
cell and platelet counts between the two groups, but neither of these was 








































































5.5 HIV-related factors  





n = 71 
P-
valuea 
Antiretroviral therapy     
Prior ART  27 (46.6) 36 (50.7) 0.639 
Median duration ART, months (IQR) 12.5 (37) 27 (11.5) 0.2024 
Default ARTb 7/27 (25.9) 0 (0.0) 0.003 
Viral load     
Median viral load, log10 copies/ml (range) 4.58 (0-6.38) 4.13 (0-4.84) 0.28 
Viral suppression on ART (<20 copies/ml) 10/20 (50) 19/36 (52.8)  
CD4+ T-lymphocyte count    
Median CD4 count, cells/µl (IQR)* 208.5 (106-382) 322.5 (182.5-483.8) 0.0121 
Median CD4 nadir, cells/µl (IQR) 112 (34-270.8) 179 (130-304) 0.0068 
Median CD4 on treatment, cells/µl 288.5 305 0.3359 
Median CD4 count off treatment, cells/µl 207 327.5 0.0402 
Documented CD4 count < 6 mo prior to stroke  18/58 (31)   
Drop in CD4 count >10cells/µl post-stroke  5/18 (27.8)   
 
Abbreviations: ART, antiretroviral therapy 
Values are depicted as No. (%), unless otherwise indicated  
*Missing data; pairwise deletion used in analysis 
aP value was calculated for categorical variables using Fisher’s 2-sided exact test or Pearson’s Chi-square test. P-
values for continuous variables were derived with the t-test or two-sample Wilcoxon rank-sum (Mann-Whitney) test.   
bExpressed as No. (%) of those previously on ART 
 
 
A similar proportion of the stroke and control groups (46.6%; 50.7%) had been 
exposed to ART prior to enrolment. Treatment duration for the controls was 
more than twice that of the stroke group (median of 27 months vs 12.5 months, 
p=0.2024). In the stroke group, 25.9% of those who had been on prior ART 
had defaulted treatment, whilst none of the controls had interrupted therapy 
(p=0.003).  
 
The stroke group had a lower CD4 count compared with the controls (median 
208.5 cells/µl vs 322.5 cells/µl, p=0.012). Individuals with stroke also had a 
lower CD4 nadir than the controls (median 112 cells/µl vs 179 cells/µl, 
p=0.008). Untreated individuals in the stroke group had a lower CD4 count 
than untreated controls (median 207 cells/µl, vs 327.5 cells/µl, p=0.04). 31% 
of stroke patients had a CD4 count documented at their local clinic within 6 
months prior to their stroke. Of those, 27.8% had a drop in their CD4 count >10 
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cells/µl after their stroke. In the stroke group, median viral load was 4.58 log10 
copies/ml and 50% of those on ART were virally suppressed. Amongst the 
controls, median viral load was 4.13 log10 copies/ml, with effective viral 

































Figure 5.5. Treatment status.  
 
Defaulters are expressed as the proportion of those who had been on prior ART, who had interrupted 
treatment at the time of enrolment.  
P <0.01 




Figure 5.6. CD4 count and CD4 nadir, median with IQR   
Strokes
Controls 
P <0.05 P <0.01 
179 
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The stroke group had higher median VCAM-1, TNF-a, VEGF, MCP-1, IL-6 and 
IL-10 in comparison to the controls. Median E-selectin, Endothelin-1, ICAM-1 




































































































































p <.0001p =.0294p = .0002












Figure 5.7. Endothelial biomarkers that were statistically significantly different between the stroke 
and control groups, median with IQR 
Figure 5.8. Endothelial biomarkers that were not statistically significantly different between the 







5.7 Stroke characteristics  
 




Oxfordshire Community Stroke Project Classification   
PACI 40 (69) 
TACI 10 (17.2) 
LACI 3 (5.2) 
POCI 5 (8.6) 
Stroke Severity Scores   
Mean NIHSS (SD)  10.5 (7.1) 
Modified Rankin Scale (mRS)  
mRS 0 1 (1.7) 
mRS 1 5 (8.6) 
mRS 2 9 (15.5) 
mRS 3 10 (17.2) 
mRS 4 24 (41.4) 
mRS 5 9 (15.5) 
mRS 6 0 
Died 3 (5.2) 
Cause of Stroke  
 
Non-atherosclerotic vasculopathy 14 (24.1) 
Opportunistic infections 
 
VZV 9 (15.5) 
TB 0 (0.0) 
Cryptococcal meningitis 0 (0.0) 
Syphilis 4 (6.9) 
Cardioembolism 9 (15.5) 
HIV-associated vasculitis 4 (6.9) 
Small vessel disease 3 (5.2) 
Accelerated atherosclerotic vasculopathy 3 (5.2) 
Cryptogenic 3 (5.2) 
Incomplete evaluation 6 (10.3) 
Other determined cause 3 (5.2) 
Confirmed cause 40 (68.97) 
Probable Cause 9 (15.5) 
Unknown cause 9 (15.5) 
 
Abbreviations: LACI, lacunar infarction; mRS, modified Rankin Scale; NIHSS, National Institutes of Health 
Stroke Scale; PACI, partial anterior circulation infarction; POCI, posterior circulation infarction; TACI, total 
anterior circulation infarction; TB, tuberculosis; VZV, varicella zoster virus; 
Cause of stroke determined using the algorithm for arterial ischemic stroke in HIV (Benjamin, Bryer, et al., 
2016) 





By Oxfordshire Community Stroke Project Classification, the clinical features 
of which were verified by brain imaging, 69% of the stroke group had features 
of partial anterior circulation infarction. The most common modified Rankin 





Figure 5.9. Stroke aetiology in the 58 HIV-infected participants with acute arterial ischaemic 
stroke. Non-atherosclerotic vasculopathy was the most frequent cause of stroke.   
 
The most frequent cause of stroke was non-atherosclerotic vasculopathy 
(24.1%), followed by VZV (15.5%) and cardio-embolism (15.5%). Of the stroke 
cases that underwent a complete evaluation, 48.1% were due to a form of HIV-
associated vasculopathy or cryptogenic stroke. Strokes due to other 























Table 5.6. Stroke participants separated by aetiology  
Strokes due to HIV-associated 
vasculopathy (n=25) 
Strokes due to alternative 
mechanisms (n=27) 
• Non-atherosclerotic vasculopathy (n=14) 
• HIV-associated vasculitis (n=4) 
• Accelerated atherosclerotic vasculopathy (n=3) 
• Cryptogenic (n=3)  
• Small vessel disease without hypertension 
(n=1) 
• Opportunistic infections (n=13) 
• Cardio-embolism (n=9) 
• Other determined cause (n=3) 
• Small vessel disease with hypertension 
(n=2)  
 










Antiretroviral therapy     
Prior ART  14 (56.0) 11 (40.7) 0.4051 
Defaulted ARTb 5/14 (35.0) 1/11 (9.1) 0.1804 
Viral load     
Median viral load, log10 copies/ml (range) 3.61 (0-6.22) 4.79 (0-5.49) 0.3206 
CD4+ T-lymphocyte count    
Median CD4 count, cells/µl (range) 207 (6-711) 271 (6-926) 0.0623 
 
Abbreviations: ART, combined antiretroviral therapy 
Values are depicted as No. (%), unless otherwise indicated  
aP value was calculated for categorical variables using Fisher’s 2-sided exact test or Pearson’s Chi-square test. 
P-values for continuous variables were analysed with the t-test or two-sample Wilcoxon rank-sum (Mann-
Whitney) test.  
bExpressed as No. (%) of those previously on ART 
 
 
There was no statistically significant difference in the proportion of patients on 
ART, median viral load or median CD4 counts between the stroke groups 
separated by aetiology. The observed trend was towards a lower CD4 count, 
















In the HIV-associated vasculopathy group, most participants were treatment-
naïve. 42.9% of those with strokes due to non-atherosclerotic vasculopathy 
were treatment-naïve, with an additional 42.9% on treatment for 7-12 months 
or >1 year. All of those with strokes due to HIV-associated vasculitis had 
defaulted treatment. In the group with strokes due to alternative mechanisms, 
Figure 5.10. Treatment status of participants with stroke due to HIV-associated vasculopathy 

























Small vessel disease without HPT
Cryptogenic





















Small vessel disease with HPT
Other determined cause





















Small vessel disease with HPT
Other determined cause
Figure 5.11. Treatment status of participants with stroke due to alternative mechanisms  
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69.2% of those with opportunistic infections were treatment-naïve, with none 
having started ART in the prior 6 months.  
 
Figure 5.12 demonstrates that the strokes due to non-atherosclerotic 
vasculopathy and HIV-associated vasculitis, and opportunistic infections, 
comprising 31% and 22.4% of all strokes respectively, occurred at lower 






























Non-atherosclerotic vasculopathy & HIV-associated vasculitis
Other HIV-asscoiated vasculopathies
Figure 5.12. Median CD4 counts of strokes by aetiology 
*Kruskal-Wallis test, approximate p-value   
Opportunistic infections
Other alternative mechanisms
Non-atherosclerotic vasculopathy & HIV-associated vasculitis
Other HIV-asscoiated vasculopathies
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5.8 Consensus sequences and dataset similarity  
 








Figure 5.13. Consensus sequence of all participants with the histogram depicting amino acid variability at each position. Positions 24, 29 and 
68 show more than 50% variability.    
1 11 21 31 41 51 61 72 
Figure 5.14. Consensus sequence of stroke group with the histogram depicting amino acid variability at each position. Positions 24, 29, 58 and 
68 show more than 50% variability.   
1 11 21 31 41 51 61 72 
Figure 5.15. Consensus sequence of control group with the histogram depicting amino acid variability at each position. Positions 24, 29, 68 
and 69 show more than 50% variability.  
1 11 21 31 41 51 61 72 
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1 11 21 31 41 51 61 72 
1 11 21 31 41 51 61 72 
Figure 5.16. Consensus sequences of strokes due to alternative mechanisms, with the histogram depicting amino acid variability at each 
position. Positions 24, 29, 58 and 68 show more than 50% variability.  
Figure 5.17. Consensus sequence of strokes due to HIV-associated vasculopathy, with the histogram depicting amino acid variability at 
each position. Positions 19, 29, 58 and 68 show more than 50% variability. X indicates an ambiguous symbol where no majority amino acid 
can be found.  
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5.8.3 Visualisation of stroke sequences relative to control consensus   
 
  
Figure 5.18. SeqPublish alignment of the stroke sequences (each participant identified by YSH…) in 
relation to the consensus sequence of the control dataset at the top of the figure. Identical residues 
are represented with dashes. The red highlighted letters indicate the signature amino acids for the 
stroke group. The green boxed area represents the chemotactic domain. The yellow boxed area 
represents the neurotoxic domain.   
 1          11          21          31          41          51         61           72              
CONTROL 
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5.9 Signature pattern analysis  
5.9.1 Signature pattern analysis of stroke and control groups 
Signature pattern analysis identified two signature amino acids in the stroke 
group relative to the controls. At position 21, the signature amino acid for the 
stroke group was proline. The most common amino acid at this position in the 
control group was alanine (p=0.003). At position 29, the signature amino acid 
for the stroke group was histidine. The most common amino acid at this 






























Table 5.8. Signature amino acids identified by VESPA for the stroke 
group relative to the control group. The p-value was derived with Fisher’s 
exact test 
Signature amino acids for stroke group P H 
Frequency among stroke set   0.690 0.310 
Frequency among control set   0.437 0.113 
Control amino acids A K 
Frequency among stroke set 0.293 0.172 
Frequency among control set 0.563 0.451 
Alignment position 21 29 
Mutation A21P K29H 




5.9.2 Signature pattern analysis of strokes separated by aetiology 
 
Signature pattern analysis identified one signature amino acid that was unique 
to the strokes due to alternative mechanisms, relative to the strokes due to 
HIV-associated vasculopathy. At position 58, threonine was the signature 
amino acid for the strokes due to alternative mechanisms, whilst alanine was 
the most common amino acid at this position in the strokes due to HIV-






Table 5.9. Signature amino acid residue identified by VESPA for the strokes due to alternative 
mechanisms relative to the strokes due to HIV-associated vasculopathy. The p-value was 
derived with Fisher’s exact test.  
 
Signature amino acids for strokes of alternative mechanisms T 
Frequency among alternative mechanisms set 0.538 
Frequency among HIV-associated vasculopathy set 0.458 
HIV-associated vasculopathy amino acids A 
Frequency among alternative mechanisms set 0.462 
Frequency among HIV-associated vasculopathy set 0.542 




5.9.3 Visualisation of signature amino acids identified by VESPA  
 Figure 5.19. Weblogo depicting amino acids representing 
stroke group sequences from position 20 to 31. The signature 
positions are highlighted with a red box.  
Figure 5.20. Weblogo depicting amino acids representing 
control group sequences from position 20 to 31. The 
signature positions are highlighted with a red box.   
Figure 5.21. Weblogo depicting amino acids representing 
strokes due to alternative mechanisms from position 50 to 60. 
The signature position is highlighted with a red box.   
Figure 5.22. Weblogo depicting amino acids representing 
strokes due to HIV-associated vasculopathy from position 50 
to 60. The signature position is highlighted with a red box.   
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5.10 Selection pressure on the stroke and control groups   
 
5.10.1 Selection pressure on the stroke group  
SLAC (Job ID upload.331776652031340.1) found 8 positively-selected sites 
in the stroke group. Of the signature residues, position 21 was a neutral site in 
the stroke group, with no significant difference in rates of non-synonymous and 
synonymous substitutions at that position. Positions 29 and 58 were under 
positive selection in the stroke group.  
 
At position 29, most substitutions were between histidine and tyrosine, with the 
assumption that histidine was replaced by tyrosine. However, the phylogenetic 
tree produced by the SLAC analysis is unrooted, so the directionality of the 
substitutions is uncertain.   
 
At position 58, all non-synonymous substitutions were between alanine and 
threonine, with 62.5% of transitions away from threonine towards alanine, but 
once again, the unrooted phylogenetic tree means that reversed directionality 
is also possible.  
 









2 0 8 0.08 
4 0 7 0.09 
19 3 33 0.07 
  29* 5.33 41.67 0.07 
36 1 13 0.03 
   58** 0 8 0.04 
68 0 25 0.00 
69 0 15 0.03 
a Probability of observing as many or fewer synonymous changes, computed using an extended binomial distribution. 
Interpreted as the p-value for positively selected sites. 
*Signature residue identified on signature pattern analysis between strokes and controls. 
**Signature residue identified on signature pattern analysis within the stroke group.  
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5.10.2 Selection pressure on the control group  
SLAC (Job ID upload.113973080424211.1) found 7 positively-selected sites 
in the stroke group. Of the signature residues between the strokes and 
controls, position 21 was under positive selection, whilst position 29 was a 
neutral site in the control group, with no significant difference in rates of non-
synonymous and synonymous substitutions (see section 2.8.2.1).  
 
At position 21, all non-synonymous substitutions were between alanine and 
proline, with the majority of transitions estimated to be from alanine to proline. 
However, the unrooted phylogenetic tree produced by the SLAC analysis is 
unrooted, so the directionality of the substitutions is uncertain.  
 










4 0 15 0.01 
 21* 1 11 0.05 
58 0 10 0.02 
67 0 14 0.02 
68 0 19 0.00 
69 0 22 0.00 
70 1 8 0.08 
a Probability of observing as many or fewer synonymous changes, computed using an extended binomial distribution. 
Interpreted as the p-value for positively selected sites. 








5.11 Correlation of signature positions with biomarkers of 
endothelial activation and inflammation  
 
Results of the linear and logistic regression models are presented below. The 
models controlled for stroke, age, current CD4 count and treatment status.  
 
Proline at position 21 had a positive association with IL-6, relative to the other 
amino acids at that position (p=0.04). Proline was the signature amino acid for 
the stroke group at position 21. Lysine at position 29 had a negative effect on 
MCP-1, relative to the other amino acids at that position (p=0.05). Lysine was 
the most common amino acid in the control group at this position.  
 
Table 5.12. Correlation of signature positions with E-selectin 
Position Coefficient P-value (P>|t|) Model Parameters 
21P -0.2941257 0.952 F (9, 106) = 0.75 
 
Prob > F = 0.6634 
 
R2 = 0.0598 
29H -3.031126 0.624 
29K -4.078011 0.496 
29R -0.9486931 0.876 
58A -6.188187 0.197 
 
Table 5.13 Correlation of signature positions with VCAM-1 
Position Coefficient P-value (P>|t|) Model Parameters 
21P 0.0015189 0.987 F (9, 106) = 2.28 
 
Prob > F = 0.0225 
 
R2 = 0.1620 
29H 0.0519273 0.667 
29K -0.078646 0.501 
29R -0.1256439 0.292 





Table 5.14. Correlation of signature positions with ICAM-1 
Position Coefficient P-value (P>|t|) Model Parameters 
21P 0.1147528 0.519 F (9, 106) = 0.70 
 
Prob > F = 0.7082 
 
R2 = 0.0560 
29H -0.101676 0.648 
29K -0.0867685 0.688 
29R 0.017948 0.935 
58A 0.0403682 0.815 
 
Table 5.15. Correlation of signature positions with TNF-a 
Position Coefficient P-value (P>|t|) Model Parameters 
21P -0.047877 0.831 F (9, 74) = 2.23 
 
Prob > F = 0.0294 
 
R2 = 0.2131 
29H -0.0196558 0.942 
29K 0.1575572 0.551 
29R -0.0179 0.947 
58A -0.1904476 0.368 
 
Table 5.16. Correlation of signature positions with MCP-1 
Position Coefficient P-value (P>|t|) Model Parameters 
21P 0.1261866 0.276 F (9, 105) = 3.21 
 
Prob > F = 0.0018 
 
R2 = 0.2155 
29H -0.1241808 0.393 
29K -0.2772934  0.051 
29R -0.1560142 0.278 
58A 0.0261245 0.815 
 
Table 5.17. Correlation of signature positions with Endothelin-1 
Position Coefficient P-value (P>|t|) Model Parameters 
21P -0.0575325 0.647 F (9, 106) = 1.57 
 
Prob > F = 0.1349 
 
R2 = 0.1174 
29H 0.1943985 0.219 
29K 0.0219021 0.886 
29R 0.0084944 0.956 
58A -0.063859 0.601 
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Table 5.18. Correlation of signature positions with VEGF 
Position Coefficient P-value (P>|t|) Model Parameters 
21P -0.1414024 0.560 F (9, 83) = 1.88 
 
Prob > F = 0.0662 
 
R2 = 0.1693 
29H 0.4054982 0.148 
29K 0.2856484 0.324 
29R 0.1498331 0.608 
58A 0.0717865 0.753 
 
Table 5.19. Correlation of signature positions with IL-6 
Position Coefficient P-value (P>|t|) Model Parameters 
21P 1.179238 0.035 LR chi2 (9) = 8.82 
 
Prob > chi2 = 0.4542 
 
29H -0.0686666 0.912 
29K -0.0955874 0.883 
29R -0.0272182 0.966 
58A 0.2524991 0.616 
 
The Hosmer-Lemeshow test showed that this model was a good fit. (p =0.6796) 
 
Table 5.20. Correlation of signature positions with IL-10 
Position Coefficient P-value (P>|t|) Model Parameters 
21P -0.0082811 0.987 LR chi2 (9) = 19.14 
 
Prob > chi2 = 0.0240 
 
29H -0.6145017 0.323 
29K -0.5116046 0.412 
29R -0.5305942 0.397 
58A -0.4788905 0.332 
 














5.12 Summary of results   
 
5.12.1 Cohort demographics 
The HIV-infected stroke group and HIV-infected non-stroke controls were well-
matched with regards to age and gender. The ethnic profile differed between 
the groups, with the presence of individuals of Mixed Ancestry in the stroke 
group.  
5.12.2 Traditional cardiovascular risk factors 
The stroke group had a higher prevalence of diabetes, higher fasting lipid 
values, and more smoking pack-years than the control group. The control 
group had a greater carotid intima-media thickness than the stroke group, and 
a higher prevalence of ethanol use. The groups were otherwise comparable 
with regards to classical cardiovascular risk factors.  
5.12.3 HIV-related factors 
Individuals in the stroke group were statistically significantly more 
immunocompromised than their non-stroke counterparts, with a history of 
treatment interruption. There was no difference in the proportion of those on 
antiretroviral therapy, or the duration of therapy between the groups.  
5.12.4 Biomarkers of endothelial dysfunction and inflammation  
The stroke group had higher median VCAM-1, TNF-a, VEGF, MCP-1, IL-6 and 
IL-10 than the controls. Median E-selectin, Endothelin-1, ICAM-1 and IL-1b did 
not differ between the groups.  
5.12.5 Characteristics of ischaemic stroke in South African Subtype-C 
infected individuals  
Ischaemic stroke in this cohort of Subtype-C HIV-infected individuals were 
moderately severe, and predominantly a result of medium- to large-vessel 
disease. HIV-associated vasculopathy and opportunistic infections were the 
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most common causes of stroke and occurred in individuals who were mostly 
treatment-naïve, had defaulted treatment, or were on ART for >1 year.  
5.12.6  Signature patterns in stroke and control groups  
Two signature amino acids were unique to the stroke group relative to the 
controls. Proline was the signature residue at position 21 in the stroke group, 
whilst alanine was the most common amino acid at that position in the controls. 
Histidine was the signature residue for the stroke group at position 29, whilst 
lysine was the most common amino acid in the control group at the same 
position.  
5.12.7 Signature patterns in strokes of different aetiologies 
Threonine at position 58 was the signature amino acid for the individuals with 
strokes due to mechanisms other than HIV-associated vasculopathy. Those 
with strokes due to HIV-associated vasculopathy had alanine as the most 
common amino acid at this position.  
5.12.8 Positive selection pressure 
Positive selection pressure was detected at 8 sites in the stroke group, and 7 
sites in the control group. Positions 29 and 58 were under positive selection in 
the stroke group, whilst position 21 was under positive selection in the controls.  
5.12.9 Effect of Tat signature residues on biomarkers of endothelial 
dysfunction and inflammation  
Proline at position 21 was associated with a relative increase in IL-6 compared 
with alanine and other amino acids at this position. Lysine at position 29 was 
associated with a relative decrease in MCP-1 compared with histidine and 






CHAPTER SIX: DISCUSSION  
 
6.1 Introduction to discussion   
 
This study investigated the potential role of the HIV-1 Tat protein in HIV-
associated endothelial dysfunction and ischaemic stroke in a cohort of young 
HIV-1 Subtype-C-infected individuals in Cape Town, South Africa. Primarily, it 
sought to describe the amino acid profile of the Tat protein in a group of young 
HIV-infected individuals with and without acute ischaemic stroke. Furthermore, 
it sought to characterize the amino acid profile of the Tat protein in strokes of 
differing aetiology, as well as to establish whether certain positions and amino 
acid residues in the Tat protein exon 1 were significantly associated with 
biomarkers of endothelial dysfunction and inflammation measured in the 
participants.  
 
The following sections review the demographic profile of the two groups at 
baseline, before discussing the results in relation to the study hypotheses.  
6.2 Demographics of the cohort  
 
The two groups were well-matched in terms of age and gender but differed in 
ethnicity. The absence of individuals of other ethnicities in the control group 
reflected the geographically-limited sampling. Most areas of Cape Town still 
have spatial segregation of ethnic groups (Statistics South Africa, 2011b; van 
Rooyen & Barros, 2017). The control group was recruited from two community 
health centres, which, although serving a large proportion of the city’s 
population, are confined to selected areas of Cape Town. Groote Schuur 
Hospital serves a much wider geographic area, stretching from the central sub-




6.3 Traditional cerebrovascular risk factors   
 
Hypothesis 3.2.1: There are significant differences in traditional 
cerebrovascular risk factors between young HIV-infected individuals with and 
without acute ischaemic stroke. Whilst HIV may be the single most important 
risk factor for stroke in individuals <45 years, traditional cerebrovascular risk 
factors may have a synergistic effect on stroke risk in HIV-infected 
individuals.  
 
6.3.1 Traditional cerebrovascular risk factors    
 
The results supported the hypothesis that, in a young HIV-infected population, 
there are differences in conventional cerebrovascular risk factors between 
those with and without acute ischaemic stroke.  
 
The stroke group had a higher prevalence of diabetes, and their fasting 
lipogram values were higher than controls. Although these values were within 
the internationally-defined optimal range (Expert Panel on Detection, 
Evaluation, 2001; Alberti, Zimmet & Shaw, 2006), this may be explained by the 
fact that lipid values in predominantly Black African populations are lower than 
those of other ethnic groups (Steyn et al., 2005). However, interpretation of the 
lipogram comparison was limited by the large number of missing values in the 
control group. Although there was a similar proportion of current smokers 
within each group, a statistically significant higher number of individuals in the 
stroke group had a more than 10 pack-year smoking history. This may have 
increased their stroke risk relative to the controls.  
 
The groups were similar in many other respects. There were no statistically 
significant differences in hypertension, systolic blood pressure, current 
smoking, substance use, known cardiac disease, previous stroke, and waist 
circumference between the groups. These results were unexpected. The 
INTERSTROKE study demonstrated that hypertension, smoking, cardiac 
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disease are associated with ischaemic stroke in African populations 
(O’Donnell et al., 2016), and the INTERHEART study showed that waist 
circumference was a strong predictor of cardiovascular disease in Black 
Africans (Yusuf et al., 2005).   
 
Our findings therefore support the suggestion that whilst traditional 
cardiovascular risk factors may play a role in ischaemic stroke in HIV, their 
contribution is less influential than that of HIV itself (see 2.3.4.3 and 2.3.4.4). 
 
6.3.2 Carotid intima-media thickness     
 
The results of the carotid-intima media thickness (CIMT) measurements in this 
cohort confirmed that CIMT in HIV is a difficult topic to elucidate. In HIV-
uninfected individuals, greater CIMT is an independent predictor of 
cardiovascular disease and is associated with increased stroke risk in 
individuals <50 years (O’Leary et al., 1999; Lorenz et al., 2006; Li et al., 2008). 
In HIV-infected individuals however, the association is not so clear. There is 
no current consensus on the impact of HIV on CIMT, as well as its usefulness 
in predicting stroke in HIV-infected individuals.  
 
In this cohort, CIMT was not associated with ischaemic stroke in HIV. 
Unadjusted analysis showed that the control group had significantly greater 
mean CIMT measurements compared with the stroke group. The subsequent 
binomial logistic regression model demonstrated that for two individuals of the 
same age and same waist circumference and one unit difference in CIMT, the 
one with a higher CIMT has a 0.224 times lower odds of having a stroke, than 
the one with the lower CIMT. There were limitations to the analysis. Firstly, this 
was a cross-sectional analysis, and we couldn’t draw any conclusions about 
future stroke risk in these individuals. Additionally, the conclusions were based 
on incomplete CIMT data. Whilst 82.8% of the stroke group had carotid duplex 
Doppler done, only 69% of the controls had carotid imaging performed. Our 
cohort’s age-range may also limit any conclusions around the effect of HIV on 
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CIMT. A recent pooled analysis demonstrated that, in individuals aged 30-49, 
HIV itself may not affect CIMT (Hanna et al., 2016).  
 
The mean CIMT may not have been sufficient to impact stroke risk in either 
group. In a large prospective study, the minimum thickness that increased the 
hazard risk ratio for stroke, when adjusted for age, sex and other risk factors 
was 0.63mm (Lorenz et al., 2006). In this cohort of HIV-infected individuals, 
the mean CIMT did not reach this significant threshold. Thus, although the 
control group had a significantly greater CIMT, it may not have been sufficient 
to increase their stroke risk.  
 
Although it has been reported that traditional cardiovascular risk factors are 
the most important determinant of greater CIMT in HIV-infected individuals 
(Stein et al., 2013; Ssinabulya et al., 2014; Pacheco et al., 2015, 2016; 
Schoffelen et al., 2015), this was not evident in this cohort. The groups were 
in many respects similar in terms of cardiovascular risk profile, and the stroke 
group, in fact, had an increased prevalence of diabetes, higher fasting lipid 
values, and a greater pack-year smoking history. Logically, the stroke group 
should have had a greater mean CIMT than the controls, when in fact the 
inverse was true in this study.  
 
Perhaps it was the severity of HIV disease that trumped cardiovascular risk 
factors in influencing CIMT in this study. CIMT has been shown to have an 
inverse relationship with viral load (Hanna et al., 2016), and thus, the more 
immunocompromised stroke group (see section 6.4.1) could plausibly have 
had a lower CIMT than their non-stroke counterparts.   
 
The greater CIMT in the control group may also be explained by the 
differences in exposure to, and duration of, antiretroviral therapy between the 
groups. Although not significant, the control group had more than twice the 
median duration of therapy compared to the strokes, and more of the control 
participants were actually on treatment at the time of enrolment (50.7% of 
controls vs 34.5% of strokes). Several studies have shown that treated 
individuals, as well as their duration of treatment, may have an association 
 103 
with increased CIMT and sub-clinical atherosclerosis in HIV-infected 
individuals (Kwiatkowska et al., 2011; Papiţă et al., 2011; Lorenz et al., 2012; 
Krikke et al., 2017).   
 
The significance of carotid intima-media thickness in HIV remains unclear.  
More studies are needed to explore the role of CIMT as a predictor of stroke 
in HIV-infected individuals. Large prospective studies, with individuals in 
different age categories, are needed to evaluate the impact of HIV on CIMT, 
and its usefulness as a predictor of stroke in HIV-infected individuals.  
 
6.3.3 History of recent infection 
 
A history of recent infection, particularly respiratory tract infection, is common 
in stroke patients worldwide (Syrjänen et al., 1988; Grau et al., 1995; Bova, 
Bornstein & Korczyn, 1996; Das et al., 2011). VZV, manifesting either as 
chicken-pox or shingles, is also a risk factor for stroke (Gilden et al., 2000, 
2009).  
Both groups were asked to report any infection they had had within the three 
months preceding enrolment. The most commonly reported infections in the 
stroke group were a respiratory tract infection, VZV (in the form of chicken pox 
or shingles) and TB. The control group reported other types of infections that 
are not linked to stroke risk. In the stroke group, VZV rash was the second 
most frequently reported infection, and VZV vasculopathy was a relatively 
common cause of stroke in this cohort (15.4% of individuals). Interestingly, not 
all the individuals who reported VZV rash had VZV vasculopathy as the cause 
of their stroke, and not all individuals with VZV vasculopathy had reported a 
rash prior to their stroke. This highlights the diagnostic difficulty with VZV-
vasculopathy: the fact that there is often a long interval between the clinical 
syndrome and stroke, and also that a visible rash does not always precede 
VZV vasculopathy (Nagel et al., 2007). Although the same number of 
individuals reported a history of tuberculosis, none had CNS TB, and no 
strokes were due to tuberculous meningitis.  
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Our findings indicate that a history of certain opportunistic infections in HIV-
infected people should alert the clinician to an increased risk of stroke in these 
individuals. These are infections that have a propensity for vascular injury, 
such as VZV, syphilis and disseminated tuberculosis.  
 
Traditional cerebrovascular risk factors in young HIV-infected 
individuals 
 
The traditional cardiovascular risk profile in young Subtype-C HIV-infected 
individuals with acute ischaemic stroke was similar in many respects in 
comparison with age- and gender-matched HIV-infected individuals without 
acute stroke. However, diabetes, higher fasting lipid values and a greater 
pack-year history of smoking distinguished those with stroke from controls. 
Traditional cardiovascular risk factors may synergistically enhance the risk of 











6.4 HIV-related factors  
 
Hypothesis 3.2.2: Recent CD4 count, CD4 nadir and viral load are 
significantly different between young HIV-infected individuals with acute 
ischaemic stroke, and those without acute ischaemic stroke. Low CD4 count 
and elevated viral load are indicators of immunocompromise, immune 
dysregulation and increased viral replication. These factors increase 
inflammation and therefore could impact on endothelial dysfunction. 
 
6.4.1 CD4 count and CD4 nadir      
 
Our results support the hypothesis that recent CD4 count and CD4 nadir have 
an inverse association with ischaemic stroke risk.  
Immune dysregulation, from infection and loss of CD4+ T-lymphocytes, is an 
important contributor to HIV-associated endothelial dysfunction (see section 
2.3.5.2) and increases the risk of opportunistic infections. Both endothelial 
dysfunction and certain opportunistic infections are risk factors for stroke in 
HIV-infected individuals (Benjamin, Bryer, et al., 2016). Recent CD4 count has 
been shown to be more strongly associated with ischaemic stroke risk than 
CD4 nadir or viral load (Marcus et al., 2014). A low CD4 nadir is also predictive 
of long-term mortality in HIV-infected individuals (Mills et al., 2012).  
One might argue that it is possible that the CD4 count measured at enrolment 
had dropped acutely in the individuals with ischaemic stroke, thereby 
producing a false difference in the median CD4 counts between the groups. 
However, a pilot analysis to test this theory was performed. Of 18 individuals 
who had a CD4 count documented in the 6 months prior to their enrolment, 
72.2% did not have a relative decrease in CD4 count post-stroke. Furthermore, 
the stroke group also had a lower CD4 nadir, and higher rates of treatment 
interruption than the controls. Untreated individuals in the stroke group also 
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had a lower CD4 count than untreated controls.  
These factors indicate that the stroke group was more immunocompromised 
than the control group before enrolment. This may have put them at greater 
risk of stroke from HIV-associated endothelial dysfunction, opportunistic 
infections and other mechanisms related to immune dysfunction.  
 
6.4.2 Viral load  
Whilst the observed trend was towards a higher viral load in the stroke group, 
the results did not support the hypothesis that viral load was significantly 
different between young HIV-infected individuals with acute stroke, and young 
HIV-infected non-stroke controls.  
 
Exposure of the vessel wall to viral particles is postulated to be part of the 
mechanism of HIV-associated endothelial dysfunction (Benjamin et al., 2012). 
Indeed, clinical studies have demonstrated that individuals with high viral loads 
are at increased risk of stroke compared to those with viral suppression 
(Siedner, in press; The Data Collection on Adverse Events of Anti-HIV Drugs 
(DAD) Study Group, 2003; Lichtenstein et al., 2010; Chow et al., 2012; Marcus 
et al., 2014; Sico et al., 2015). Furthermore, the severity of endothelial 
dysfunction is positively correlated with high viraemia (Blum et al., 2005).  
 
In this cohort, only 21.1% of stroke patients were virally suppressed, and the 
median viral load was 4.58 log10 copies/ml. This would indicate that these 
individuals were at high risk of severe endothelial dysfunction and ischaemic 
stroke.  
 
The controls also had evidence of uncontrolled viral replication. Only 26.7% of 
the control group was virally-suppressed, and the median viral load was 4.13 
log10 copies/ml. One could argue that if viraemia was present in individuals 
without stroke, then it is either not a significant contributor to endothelial 
dysfunction, nor a good indicator of stroke risk.  
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However, the controls also showed evidence of endothelial dysfunction. 
Despite not suffering an ischaemic event, the controls had similar levels of 
adhesion and vasoconstrictor molecules compared with the stroke group. 
Furthermore, the pathogenesis and progression of endothelial dysfunction to 
stroke in HIV is complex. As suggested by Maggi et al. (Maggi, Ingrassia & 
D’Annunzio, 2008), stroke in HIV may be the result of HIV-associated 
endothelial dysfunction in conjunction with other risk factors. Whilst viraemia 
is associated with increased severity of endothelial dysfunction, it may not be 
sufficient to produce the degree of endothelial dysfunction needed to result in 
thrombosis and occlusion in all individuals.  
 
6.4.3 Antiretroviral therapy  
 
Antiretroviral therapy may improve vascular endothelial dysfunction by 
reducing viral replication rate and the incidence of opportunistic infections. 
However, recent initiation of ART may also increase the risk of stroke. 
Reconstitution of the immune system upregulates the pro-inflammatory milieu. 
This study provided further evidence to support the idea that untreated HIV, as 
well as interruption of treatment, infer greater risk for cardiovascular disease 
than antiretroviral therapy itself (The Strategies for Management of 
Antiretroviral Therapy (SMART) Study Group, 2006; Corral et al., 2009; Chow 
et al., 2012).  
Newer antiretroviral agents are considered safer in terms of cardiovascular risk 
(Worm et al., 2010). With the inclusion of treatment defaulters, only 34.5% of 
the stroke group was on treatment at enrolment, compared to 50.7% of the 
controls. The controls were also established on ART for a median of 27 
months, compared with a median of 11 months in the stroke group. This 
supports evidence that  treatment of HIV, and ART duration, have an inverse 
relationship with stroke risk (The Strategies for Management of Antiretroviral 
Therapy (SMART) Study Group, 2006; Corral et al., 2009; Chow et al., 2012).  
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The median duration of treatment for those with stroke was 11 months, which 
may have put them at higher risk of endothelial dysfunction secondary to IRIS. 
However, further examination of ART duration in the stroke group, as 
discussed in section 6.5, shows that IRIS was less likely to be a significant 
mechanism for stroke in this cohort.  
 
Immune status, antiretroviral therapy and ischaemic stroke 
 
Young HIV-infected individuals with acute ischaemic stroke are more 
immunocompromised and have higher rates of treatment interruption than 
HIV-infected individuals without acute stroke. Multiple aspects of HIV and its 
treatment have a cumulative effect on the severity of endothelial dysfunction 
and risk of progression to stroke. These include low CD4 nadir, low recent 
CD4 count, high viral load and treatment interruption. This supports evidence 
that treatment interruption and HIV disease severity may increase risk of 













6.5 Stroke characteristics  
 
I described the clinical phenotype, severity and aetiology of ischaemic stroke 
in this study. I did so in order to further the understanding of acute ischaemic 
stroke in our unique context. The stroke profile of South African Subtype-C 
infected individuals at the epicentre of the HIV epidemic is distinct from 
ischaemic stroke described in first-world cohorts.  
 
6.5.1 Stroke severity   
Most strokes were moderately severe, where affected individuals were unable 
to attend to their own bodily needs or walk unassisted (van Swieten et al., 
1988). 5.2% of individuals died following their stroke.  
 
6.5.2 Cause of stroke   
Medium- to large-vessel disease predominated, with strokes due to non-
atherosclerotic vasculopathy being the most common, followed by VZV 
vasculopathy.  
 
The spectrum of HIV-associated endothelial dysfunction is represented by 
cryptogenic stroke, small vessel disease without hypertension, non-
atherosclerotic vasculopathy, accelerated atherosclerotic vasculopathy and 
HIV-associated vasculitis. This range of phenotypes, under the umbrella-term 
of HIV-associated vasculopathy, accounted for 43.1% of all strokes in this 
cohort. Opportunistic infections were also a prominent cause of stroke: VZV 





6.5.3 HIV-associated vasculopathy and alternative mechanisms of 
stroke in HIV   
 
Further analysis of the clinical characteristics of the two stroke groups divided 
by aetiology did not detect any substantial differences in the CD4 counts or 
viral loads between the two groups. Figure 5.12 highlights the possible reason 
for the findings observed. Opportunistic infections, which comprised the 
largest proportion of strokes due to alternative mechanisms, occurred in 
individuals with a median CD4 <200 cells/µl.   
 
Similarly, non-atherosclerotic vasculopathy and HIV-associated vasculitis, 
comprising the largest proportion of strokes due to HIV-associated 
vasculopathy, occurred in individuals with a median CD4 <200 cells/µl. These 
observations support previous findings that strokes due to opportunistic 
infections occur at relatively low CD4 counts. Similarly, non-atherosclerotic 
vasculopathy and HIV-associated vasculitis also occurred in more 
immunocompromised individuals, supporting the idea that most HIV-
associated endothelial dysfunction occurs with more advanced HIV disease.  
 
However, the CD4 counts of those with HIV-associated vasculopathy covered 
a wide range, from 6 to 711 cells/µl, indicating that HIV-associated endothelial 
dysfunction is a complex phenomenon. One explanation is that the Tat protein 
has the potential to contribute to inflammation and endothelial injury at any 
CD4 count. HIV-infected cells are never fully eradicated, even when the 
immune system is restored by ART (Chun et al., 1999). Latently-infected cells 
continue to secrete Tat (see section 2.7.5.3), which may continue to contribute 
to endothelial injury in individuals with higher CD4 counts.  
 
At a lower CD4 count, with more productively infected cells, the extra-cellular 
release of viral particles and Tat may be more extensive. Thus, non-
atherosclerotic vasculopathy and HIV-associated vasculitis may not need 
additional factors to reach a threshold of thrombosis and clinical ischaemia. 
However, accelerated atherosclerotic vasculopathy occurred at higher CD4 
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counts in this cohort, suggesting that HIV-induced inflammation in these 
individuals needed the synergistic effect of traditional cardiovascular risk 
factors to reach a threshold of thrombosis and occlusion (see the “two-step 
hypothesis”, section 2.3.4.3).    
 
6.5.4 The role of IRIS in HIV-associated vasculopathy    
 
A recent study on HIV-associated ischaemic stroke in Malawi postulated that 
most strokes due to HIV-associated vasculitis and non-atherosclerotic 
vasculopathy may have been due to IRIS, with many individuals having 
recently initiated ART (Benjamin et al., 2017). In contrast, all our individuals 
with strokes due to HIV-associated vasculitis had defaulted treatment, and in 
those with non-atherosclerotic vasculopathy, 71.4% were either treatment-
naïve, had defaulted, or were on treatment for more than a year. Furthermore, 
69.2% of individuals with strokes due to opportunistic infections were also 
treatment-naïve. This suggests that the virus itself, in combination with other 
factors, rather than IRIS, contributed to endothelial dysfunction and stroke in 
this cohort. CSF analysis of Tat levels in the stroke group would have been 
needed to explore the theory that ischaemia could also be a form of chronic 
CNS IRIS, in response to ongoing levels of Tat secretion (see section 2.7.5.4) 












Ischaemic stroke in young South African individuals infected with HIV-1 
Subtype C  
 
Ischaemic stroke in young Subtype-C HIV-infected individuals in South Africa 
differs from that in the developed world. The most common cause of stroke in 
this cohort was HIV-associated vasculopathy, followed by opportunistic 
infections. The pathogenesis of these two main causes was more likely due 
to untreated or inadequately-treated HIV infection than an IRIS phenomenon. 
HIV-associated vasculopathy as a whole is a complex phenomenon, with the 
various phenotypes occurring at different CD4 counts, suggesting that they 
represent a spectrum of HIV-associated endothelial dysfunction. In 
populations of young-HIV infected individuals with a paucity of traditional 
cardiovascular risk factors, emphasis should be placed on the prevention of 
opportunistic infections and ensuring adequate antiretroviral coverage to 

























6.6 Signature pattern analysis of the Tat protein 
between strokes and controls  
 
Hypothesis 3.2.3: There are differences in Tat protein sequences between 
HIV-infected individuals with acute ischaemic stroke and non-stroke controls. 
 
The function of HIV-1 Tat may be affected by amino acid variations in its first 
exon. Amino acid substitutions, detected by signature pattern analysis, could 
result in increased endothelial damage by increasing viral replication rate, 
facilitating chemoattraction, or inducing the expression of pro-inflammatory 
cytokines. Our findings supported our hypothesis that there are signature 
differences in the amino acid composition of the Tat protein between HIV-
infected individuals with and without acute ischaemic stroke.  
 
6.6.1 Visual comparison of datasets 
The consensus sequences depicted by the CLC Sequence viewer (see section 
5.8.1 and 5.8.2, figures 5.13-5.17) allow for easy identification of the signature 
amino acids between the groups, as well as the amino acid variability in the 
sequences. The consensus sequences for the stroke and control groups are 
identical except at positions 21 and 29, and the consensus sequences for the 
divided stroke groups are identical at all residues except at position 58. 
The CLC histograms show that within the cohort of Tat-C, sequences have 
>50% site-specific variation at only four positions. The relative conservation of 
amino acids at positions 1-20 and 30-55 in this cohort probably reflects the 
importance of the N-terminal, cysteine-rich and basic domains in the Tat 
protein’s primary function. The critical role of these regions in transactivation, 
which dramatically enhances viral replication, could functionally constrain the 
degree of amino acid variability at these sites. The high degree of variability at 
positions 24, 29, 58 and 68 in the stroke group, and positions 24, 29, 68 and 
69 in the control group may reflect a lesser degree of functional restraint 
(Yamaguchi-Kabata & Gojobori, 2000). A similar picture was seen in the 
consensus sequences and histograms of the strokes separated by aetiology.  
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Both SeqPublish and the Weblogos (see sections 5.8.3 and 5.93, respectively) 
of the different groups clearly demonstrate the dominance of proline at position 
21 and histidine at position 29 in the stroke group, relative to the alanine and 
lysine at those positions in the control group. The Weblogos of the stroke group 
divided by aetiology also provides a visual confirmation of the difference in 
residues at position 58.   
 
6.6.2 A21P: Proline is a signature amino acid at position 21 in HIV-
infected individuals with acute ischaemic stroke  
 
The A21P substitution lies in the N-terminal domain of the Tat protein, which 
contributes to the initiation of transcription in the host cell (Siderovski et al., 
1992). It also mediates binding to the CREB (CBP/p300) complex, which is 
involved in promotion of initial transcription of viral RNA (Deng et al., 2000; 
Bagashev & Sawaya, 2013; Davey et al., 2014; Musinova et al., 2016). It may 
also assist with altering the response of T-lymphocytes to viral antigens, by 
suppressing antigen-induced activation (Mitola et al., 2000). Amino acid 
substitutions at this position may therefore influence HIV-1 replication by 
altering transcription or the T-lymphocyte response to infected cells.   
 
The A21P substitution is one of four substitutions described at position 21 in 
the HIV-1 Tat protein. A21P has been noted in several circulating recombinant 
forms in Cameroon (Teto et al., 2016). A21P is also present in two highly 
virulent strains from central Africa, Tat Mal and Tat Eli. In a functional study 
looking at six Tat protein isolates, Tat Mal and Tat Eli had the highest 
transactivation activity compared to viral isolates from Europe, America and 
other African regions. However, the study concluded that it was position 22 
rather than 21 that had the greatest impact on transactivation ability. A viral 
isolate from a long-term non-progressor, with a complete inability to 
transactivate, differed from all other strains with a mutation to serine at position 
22. Substitutions at position 21, whilst possibly altering the structure of the 
 115 
protein, do not seem to have a significant impact on transactivation ability 
(Peloponese et al., 1999). 
 
A study looking at Tat clones from three epidemiologically linked individuals, 
agreed with this conclusion. Whilst A21P was present in one of the individuals, 
other substitutions in the core and basic regions were more likely to have been 
responsible for the effect on transactivation ability, which was measured with 
a luciferase reporter assay (Sivakumaran et al., 2007).  
 
In summary, although the A21P mutation has been described in two highly 
virulent isolates, it was not found to be functionally significant with regards to 
altering transactivation. Whilst there are few functional studies to date, 
available research seems to indicate that it is less likely that A21P could 
enhance endothelial dysfunction by increasing viral replication rate.  
 
6.6.3 K29H: Histidine is a signature amino acid at position 29 in the 
stroke group   
The K29H mutation is one of six mutations described at position 29. K29H has 
been described in Tat-D isolates in Cameroon (Teto et al., 2016) but not in 
Tat-C isolates elsewhere in the literature. 
 
Position 29 is in the cysteine-rich and chemotactic regions. The chemotactic 
region, between residues 24 and 51, may be responsible for a significant 
proportion of monocyte and PMNL chemoattraction, as well as induction of 
VEGF and IL-8 release by affected cells (Albini, Benelli, et al., 1998; Albini, 
Ferrini, et al., 1998; Benelli et al., 2000). The cysteine-rich region is involved 
in leucocyte chemoattraction, and supports transactivation (Vene et al., 2001; 
Campbell et al., 2004). It has been suggested that amino acid substitutions in 
this region are detrimental to transactivational ability (Li et al., 2009). Although 
most studies show that the basic domain is sufficient for transactivation, Tat 
Oyi, a strain isolated from a seropositive long-term non-progressor in Gabon, 
is unable to transactivate, and this loss of function has been attributed to a 
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C22S mutation in the cysteine-rich region (Peloponese et al., 1999; Campbell 
& Loret, 2009).  
 
Lysine, the most common amino acid at position 29 in the control group, may 
play an important role in the physical and functional properties of the Tat 
protein. Lysine-associated hydrogen bonds are important for protein stability, 
and lysine residues at certain positions in the cysteine-rich, core, and basic 
regions could enhance Tat activity. Whilst reduced transactivation has been 
attributed to loss of lysine at positions 28, 41, 50, and 51, it has been 
suggested that lysine at other positions may only play a minor role in 
transactivation ability (Desfosses et al., 2005). However, in other small studies, 
mutation of lysine to another amino acid at position 29 reduced 
transactivational activity, and may affect HIV-1 RNA splicing (Berro et al., 
2006; Yukl et al., 2009). Whether the mutation of lysine to histidine, as seen in 
this cohort, may have the same effect, needs further exploration.  
 
In a recent study on HAND, looking at Subtype-C Tat sequences in an Indian 
cohort, the presence of lysine at position 29 appeared to have a clinically 
protective role. Lysine at position 29 was more common among participants 
without cognitive impairment, and arginine at this position was a signature 
residue in those with higher Global Deficit Scores. This substitution changed 
the secondary structure of the dicysteine motif, which may have altered Tat’s 
neurotoxic potential (Tilghman et al., 2014).  
 
The difficulty of drawing conclusions from functional analysis of mutations in 
the cysteine-rich region is illustrated by the recent debate with regards to the 
dicysteine motif at positions 30 and 31. Functional analysis of mutations in vitro 
may not reflect the clinical, in vivo effects of substitutions at these residues  (de 
Almeida et al., 2013; Paul et al., 2014, 2017). The lack of clear clinical 
implications of the laboratory findings around the C30C31S mutation implies 
that functional studies are not straightforward, and other genetic variations 
may be responsible for the observed effects in vitro. 
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In summary, any mutation in the cysteine-rich and chemotactic regions may 
have an impact on the transactivational and/or chemoattractant properties of 
Tat, potentially altering its effects on viral replication and endothelial 
dysfunction. The study on Tat-C in HAND has presented the possibility that 
the loss of lysine at position 29 may alter the pathogenic potential of the Tat 
protein. Thus, the loss of lysine at position 29 in this cohort may have rendered 
the stroke group more vulnerable to endothelial dysfunction, by altering the 
chemoattractant abilities of the Tat protein.  
 
Specific amino acids in the HIV-1 Tat protein are significantly 
associated with ischaemic stroke in young HIV-infected individuals  
 
Two signature amino acids in Tat exon 1 are significantly associated with 
acute ischaemic stroke in young Subtype-C HIV-infected individuals in South 
Africa. These signature residues are located in regions important for the 
initiation of transactivation and for chemoattraction. Mutations in these 
domains may alter HIV-1 replication and exposure of vascular endothelium to 
inflammatory cells. This could affect the degree of HIV-associated endothelial 
dysfunction and stroke risk. Functional studies are needed to identify the 















6.7 Signature pattern analysis of the Tat protein 
between strokes of differing aetiologies   
 
Hypothesis 3.2.4: There are differences in Tat protein sequences between 
individuals with strokes due to HIV-associated vasculopathy and strokes due 
to alternative mechanisms. 
 
Individuals with strokes due to HIV-associated vasculopathy may have a 
greater degree of direct HIV-associated endothelial dysfunction than those 
with strokes due to other mechanisms, such as opportunistic infections. 
Therefore, I wondered whether the extent of endothelial dysfunction may be 
altered by differences in the amino acid composition of the Tat protein in these 
individuals. Although there was a signature amino acid difference between the 
two groups, it lacked significance and the hypothesis could not be fully 
supported.  
 
6.7.1 A58T: Threonine is a signature amino acid at position 58 in strokes 
due to alternative mechanisms  
The A58T substitution is in the basic domain, and within the neurotoxic region 
defined by Albini et al.   
The basic domain is important for transactivation, TAR-binding, and the uptake 
of Tat into cells via a nuclear localisation signal (Loret et al., 1992). Mutations 
in this region, with the loss of residues key to translocation, may result in a 
non-functional Tat protein in the cytoplasm (Hauber, Malim & Cullen, 1989; 
Vives, Brodin & Lebleu, 1997). Although residues 49-57 may be sufficient for 
binding to TAR, the adjacent core and glutamine-rich regions synergistically 
optimise TAR interaction (Luo & Peterlin, 1993; Jeang, Xiao & Rich, 1999). 
The glutamine-rich region may facilitate transactivation by stabilizing the Tat-
TAR complex, and augments viral replication (Loret et al., 1992; Li et al., 
2012). The basic region cooperates with the cysteine-rich region to mediate 
lymphocyte adhesion and migration across the endothelium. The two regions 
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facilitate the formation of homodimers that mediate heparin-sulphate 
proteoglycan-dependent lymphocyte adhesion to endothelial cells (Urbinati et 
al., 2009). The basic domain is also chemotactic for dendritic cells (Vene et 
al., 2001).   
Importantly, the basic domain is primarily responsible for the activation of 
MAPK (Rusnati et al., 2001), NF-kB and TNF-a, the downstream effects of 
which activate many other pro-inflammatory molecules, including E-selectin, 
IL-1b (Nath et al., 1999), MCP-1 (Weiss et al., 1999; Toborek et al., 2002), and 
IL-6 (Philippon et al., 1994; Demarchi, Gutierrez & Giacca, 1999; Cota-Gomez 
et al., 2002; Nookala & Kumar, 2014).  
A58T has been described in a circulating recombinant form in Cameroon, and 
threonine at position 58 is thought to be a phosphorylation site, allowing for 
post-translational modification of the Tat protein (Teto et al., 2016). The A58T 
mutation was first detected in a fast-replicating viral isolate with increased 
transactivation ability (Leguern et al., 1993). Analyses with real time 
quantitative PCR and ELISA has shown that viral isolates with the A58T 
mutation are potent transactivators when compared to wild-type viral isolates. 
However, the A58T mutation displays reduced modulation of cellular genes 
similar to those induced by interferon (IFN) (Kukkonen et al., 2014). Viral 
isolates with the Tat A58T mutation have impaired ability to up- or down-
regulate interferon-stimulated genes (ISGs), which are part of the innate 
immune response to viruses.  
There are various theories around the clinical effects of ISG modulation. On 
the one hand, upregulation of ISGs can reduce viral replication by activating 
anti-viral factors. In some cell types, this may result in viral latency, and allow 
the virus to escape immune surveillance. However, direct stimulation of innate 
immunity by ISGs may also activate macrophages, which produce cytokines. 
A strong innate immune response to the virus plays an important role in the 
persistent immune activation seen in HIV infection, which is hypothesized to 
contribute to endothelial dysfunction (Feinstein et al., 2016). 
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Conversely, whilst reduced modulation of ISGs may allow viral replication to 
occur, it may also attenuate stimulation of innate immunity. This would 
theoretically reduce chronic persistent inflammation and bystander injury to 
endothelial cells (Kukkonen et al., 2014). This hypothesis comes from studies 
done on natural hosts of the simian immunodeficiency virus (SIV). Despite high 
levels of viral replication, these animals have a limited anti-viral immune 
response, which reduces the generalised immune activation and bystander 
injury seen in non-natural hosts of SIV. One of the proposed mechanisms for 
the attenuation in chronic persistent inflammation is down-regulation of IFN-
stimulated pathways (Silvestri et al., 2003; Bosinger et al., 2009; Jacquelin et 
al., 2009).  
The A58T variant seen in the group with strokes due to alternative 
mechanisms could reduce Tat’s ability to modulate ISGs. In these individuals, 
reduced provocation of innate immunity may have slowed the rate of chronic 
persistent inflammation and thus the progression of HIV-associated 
endothelial dysfunction. It is possible that other mechanisms in this group, 
such as opportunistic infections, may have superseded HIV-associated 
vasculopathy as the cause of vascular injury, thrombosis and occlusion.  
A small study comparing Tat protein variability in HIV-infected individuals with 
different rates of disease progression found the A58T substitution in 25% of 
long-term survivors. However, although A58T has been associated with 
differences in replication rates, no functional differences could be detected 
using the transfection-expression method in vitro (Quinones-Mateu et al., 
1998).  
Thus, the A58T mutation could have less of an impact on HIV-associated 
endothelial dysfunction and HIV-associated vasculopathy by attenuating 
chronic persistent inflammation. However, the evidence for reduced chronic 
persistent inflammation in HIV-infected individuals with the A58T mutation is 
far from robust, and other studies have found that A58T is not a more potent 
transactivator than other isolates. Furthermore, although A58T was identified 
as a signature amino acid in this study, subsequent analysis with the Fisher’s 
exact test showed that it was not statistically significant.  
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A signature amino acid in the HIV-1 Tat protein distinguishes stroke 
pathogenesis in young HIV-infected individuals with acute ischaemic 
stroke  
  
A signature amino acid in the basic region of Tat exon 1 distinguishes stroke 
due to HIV-associated vasculopathy from stroke due to alternative 
mechanisms. The impact of the A58T mutation in strokes due to alternative 
mechanisms is unclear, but may alter modulation of innate immunity and 
chronic persistent inflammation, as well as the induction of pro-inflammatory 
molecules. Further signature pattern analysis with a larger number of 
patients is needed to confirm whether this signature pattern persists. 
Functional studies are also needed to assess the impact of A58T viral 




















6.8 Selection pressure in the stroke and control groups  
 
The Tat protein is continually evolving due to host selection pressures such as 
host immune response, antiretroviral therapy and concomitant infections. 
Positive selection occurs when a non-synonymous substitution, which may 
alter the structure and/or function of a protein, confers an evolutionary 
advantage to the virus. It may increase viral fitness by improving viral 
replication rate, evading the host immune response or developing resistance 
to an antiretroviral medication. I was interested to see whether positive 
selection was present at any of the signature sites identified by VESPA, as 
well as to determine which other positions were important for improving viral 
fitness in this cohort.   
 
Whilst I can be reasonably confident that the SLAC analysis accurately 
identifies sites under positive selection, I can only comment on the 
directionality of the amino acid substitutions with caution. This is because 
SLAC produces an unrooted phylogenetic tree, which means that reversed 
directionality is also possible. The SLAC method identified 8 amino acid sites 
in the stroke group and 7 sites in the control group that were under positive 
selection pressure. The majority of the sites under positive selection in both 
groups were in the N-terminal or basic domains, which suggests that positive 
selection was greatest in the regions that would improve viral replication via 
enhancement of transcription.  
 
6.8.1 Position 21 
Position 21 was under positive selection in the control group but evolving 
neutrally in the stroke group. In the control group, the majority of transitions 
were from alanine to proline, suggesting that proline (the signature amino acid 






6.8.2 Position 29 
Position 29 was under positive selection pressure in the stroke group but not 
the control group. With the majority of transitions between histidine and 
tyrosine, it suggests that either tyrosine or histidine is a favourable mutation 
for viral fitness at position 29 in the stroke group. Lysine, the most common 
amino acid in the control group, was only selected for in 17.9% or 3.6% of non-
synonymous substitutions in the stroke group, depending on the directionality 
of the transition. Tilghman et al. detected positive selection pressure at position 
29 in Tat-C in participants with normal cognition, with the presumed transition 
away from the signature amino acid associated with neurocognitive 
impairment (Tilghman et al., 2014). The signature pattern analyses of our 
participants, as well as those of Tilghman et al., show that lysine at position 29 
is more likely to be present in individuals without stroke or neurocognitive 
impairment, hinting at a possible protective role in disease pathogenesis. 
However, lysine may not confer an advantage to viral fitness: in both studies, 
lysine was not noted to be predominantly selected for in those positions under 
positive selection pressure.  
 
6.8.3 Position 58 
Position 58, a signature residue detected in the comparison between the 
strokes of differing aetiologies, was also under positive selection pressure in 
the stroke group. 62.5% of transitions were presumed to be from threonine to 
alanine, which is the signature amino acid at position 58 in strokes due to HIV-
associated vasculopathy. The transition away from threonine at position 58 
may have to do with the fact that it is a phosphorylation site, which could alter 
the post-translational modification of the Tat protein, perhaps to the detriment 
of viral fitness. Positive selection analysis was not done on the stroke group 
separated by aetiology, which would have given a better indication of whether 
the amino acid transitions were for, or against, the signature amino acids 
identified in HIV-associated vasculopathy versus alternative mechanisms. This 
is an avenue for further exploration.  
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Specific amino acids in the HIV-1 Tat protein associated with stroke and 
endothelial dysfunction are under positive selection in a cohort of 
young HIV-infected individuals 
 
Analysis of selection pressure in this cohort showed that all signature amino 
acids associated with stroke and HIV-associated vasculopathy were under 
positive selection. These findings indicate that the stroke group’s signature 
amino acids may have been more advantageous to viral fitness than those of 
the controls. Alanine at position 58 was also selected for in the stroke group, 
indicating that the amino acid common to the group with stroke due to HIV-




















6.9. Serum biomarker analysis  
 
Hypothesis 3.2.5: Certain positions and amino acids in the Tat protein are 
specifically associated with biomarkers of endothelial activation and 
inflammation. 
 
6.9.1 Evaluation of biomarkers between the groups   
 
I had access to 10 biomarkers of endothelial activation and inflammation, 
measured in all participants on enrolment into the study. My expectations were 
that all 10 biomarkers would be significantly higher in the stroke group, due to 
the recent ischaemic insult.  
 
Only 6 of the 10 biomarkers were statistically significantly higher in the stroke 
group. Median E-selectin, Endothelin-1, ICAM-1 and IL-b were not significantly 
different between strokes and controls. This highlights the likelihood that most 
HIV-infected individuals have a degree of underlying endothelial dysfunction, 
with a persistent elevation of vasoconstrictors and adhesion molecules.  
 
6.9.2 Correlation of signature residues with biomarkers of endothelial 
activation and inflammation    
Due to limited resources, I was unable to assess the effect of the signature 
mutations with in vitro studies. I therefore attempted to explore the effect of the 
Tat protein signature residues on endothelial dysfunction with statistical 
methods. I controlled for age, stroke, treatment status and CD4 count in an 
attempt to isolate the effect of the Tat protein signature residues on activation 
of endothelial biomarkers.  
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Proline, the signature residue at position 21 in the stroke group, was 
associated with a relative increase in IL-6 compared with other amino acids, 
including alanine, which was the most common amino acid at position 21 in 
the control group. It suggests that the predominance of proline at position 21 
in the stroke group may have contributed to the upregulation of IL-6, which is 
a pro-inflammatory cytokine, and may increase stroke risk (see section 2.4.2). 
In most studies, functions of the Tat protein, such as upregulation of certain 
cytokines, have been localised to a single domain. However, studies have also 
shown that other domains can perform the same function, albeit less strongly, 
or have a supporting role (see Table 2.2). Whilst the upregulation of IL-6 has 
been localised to the basic domain (Ambrosino et al., 1997), the association 
of IL-6 with the N-terminal in this study provides evidence to support the theory 
that more than one region contributes to the transcription of various genes.  
 
Lysine, the most common amino acid in the control group at position 29, was 
significantly associated with a relative decrease in MCP-1, compared with 
histidine, and other amino acids. Histidine is the signature residue at this 
position in the stroke group. The Tat protein has been shown to upregulate 
MCP-1, which is primarily responsible for macrophage chemotaxis (Weiss et 
al., 1999). Macrophage/monocyte invasion and sub-endothelial trapping are 
postulated to be integral to the development of HIV-associated vasculopathy 
(see section 2.3.5.2). This finding is physiologically plausible, as position 29 
lies within the chemotactic domain described by Albini et al. (Albini, Benelli, et 
al., 1998). The predominance of lysine at this position in the control group 
would suggest that it may have a relatively reduced effect on chemoattraction 
of inflammatory cells to vascular endothelium, and therefore on Tat-mediated 
endothelial dysfunction, than histidine or other amino acids at this position.  
 
Further work on the Tat protein’s influence on endothelial and pro-
inflammatory biomarkers is needed. Tat could emerge as having an integral 
role in endothelial disruption. It may be possible to develop therapies that 
counter the Tat protein’s contribution to the chronic persistent inflammation 
seen in HIV. It is yet unclear as to how effectively statin therapy reduces 
subclinical vascular disease in HIV (d’Ettorre et al., 2016), and we await the 
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conclusion of the current REPRIEVE trial for further clarification (National 
Institute of Allergy and Infectious Diseases, 2017). However, statin therapy 
has directly and indirectly been shown to downregulate the expression or 
activation of certain endothelial biomarkers induced by the Tat protein 
(Chauhan et al., 2007; Sui et al., 2007; Andras et al., 2008), and may attenuate 
the paracrine effects of the Tat protein on vascular endothelium. Additionally, 
there is currently a Tat vaccine that shows promise in the development of Tat-
neutralising antibodies in human subjects (Loret et al., 2016). 
 
Specific amino acids in the HIV-1 Tat protein are associated with 
modulation of IL-6 and MCP-1 
 
This study demonstrated how the Tat protein may propagate endothelial 
activation and dysfunction in young HIV-infected individuals. Specific amino 
acids were associated with relative increases or decreases in biomarkers of 
endothelial activation. Future work could include improving statistical models, 
with the aim of creating a model that would examine all 72 positions, and 
their effect on the endothelial markers measured in this cohort. Further 
evidence supporting the role of the Tat protein in upregulation of endothelial 
biomarkers would emphasise the importance of the current trials into statin 
therapy and Tat vaccines. Neutralisation of Tat could assist in reducing HIV-











6.10 Potential limitations of this study  
 
6.10.1 Study participants  
The clinical information and blood samples utilised in this sub-study were 
obtained from participants originally recruited for a larger study four to seven 
years prior to this research. The advantage of using participants from a larger 
study was that the contributions made by the original participants could be 
honoured by allowing additional research to examine multiple aspects of the 
role of HIV infection in stroke. However, the larger study was not powered for 
the specific analysis of the Tat protein, and the sample size was therefore fixed 
for this particular sub-study. There were also some missing values for certain 
variables, most notably fasting lipogram, and carotid intima-media thickness. 
This was handled with pair-wise deletion, and for variables where there was a 
large number of missing values, the actual number of individuals analysed was 
indicated in the results table.  
6.10.2 Study design  
This study evaluates the prevalence of associative factors and clinical 
outcomes at a single time point in the sample. Longitudinal follow-up was not 
possible in this study due to resource and time constraints. Follow-up analyses 
could have examined whether the biomarkers measured in the stroke group 
decreased after the acute ischaemic event. Longitudinal follow-up could also 
have assessed whether any control participants developed ischaemic stroke. 
However, the Tat protein is constantly evolving due to host selection 
pressures. The predominant quasispecies in an individual can change over 
time, and any control participants who developed stroke would have to 
undergo re-sampling at the time of new stroke onset to determine whether they 
had acquired new mutations in the Tat protein since enrolment into the present 
study. It would have been interesting to follow-up on those control participants 
who possessed the mutation that was predominant in the stroke group, to see 
if they will develop ischaemic stroke.  
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6.10.3 Sources of bias  
A potential sampling and selection bias exists in this study. Cases and controls 
were recruited by convenience sampling. As all participants were recruited 
through the stroke services of a tertiary hospital and its affiliated secondary 
hospitals, there may have been bias in favour of more severe strokes. Patients 
presenting to primary facilities with minor strokes may not have been referred 
for further assessment. This study took place in Cape Town, South Africa. The 
Groote Schuur Stroke Service receives patients from a wider area of Cape 
Town, increasing the chance of more accurate representation of the city’s 
population. The controls were recruited from two community health centres, 
each of which serves a specific geographical area of the Cape Town 
metropole. The difference in ethnic profile seen between the groups may have 
been a result of this geographical discrepancy. Nevertheless, almost 90% of 
the stroke group was of similar ethnic background to the control group, 
meaning that the groups were actually quite similar at baseline. 
6.10.4 VZV testing  
VZV-specific IgG testing, the recommended method for VZV vasculopathy 
diagnosis, was not available in our setting. To diagnose VZV vasculopathy, we 
used VZV-PCR, which is less sensitive than VZV-specific antibody testing 
(Nagel et al., 2007). This may have led to in under-diagnosis of VZV as a cause 
of stroke. However, the prevalence of VZV-vasculopathy in our cohort was 
similar to that of a recent study of HIV-infected individuals with stroke that had 
access to VZV-specific antibody testing in the CSF (Benjamin et al., 2017). 
The distinction between VZV vasculopathy and non-atherosclerotic 
vasculopathy is currently difficult, due to the similarities between VZV 
vasculopathy and other vasculopathies on clinical, radiographic and CSF 






6.10.5 Sequencing methods  
Sanger sequencing, rather than next-generation sequencing, was used to 
obtain the tat exon 1 sequence in the peripheral blood of each participant. This 
differs from next-generation sequencing, which can identify all the 
quasispecies present within an individual (Barzon et al., 2011). However, 
although there is always intra-individual variability, a number of dominant 
sequence clusters exist (Yin et al., 2012). Sanger sequencing identifies the 
most prevalent sequence (Dampier et al., 2017), which is sufficient to estimate 
the response of the virus to selection pressures, such as antiretroviral therapy, 
host immune response and environmental factors, and also most likely to have 
the largest bystander effect (Dampier et al., 2016).  
6.10.6 Analysis of Subtype-C   
Analysis of Tat protein signature patterns was limited to Subtype-C sequences. 
An advantage of this is that Subtype-C represents 52% of all HIV-1 infections 
worldwide, which means that our findings may be relevant to the majority of 
HIV-infected individuals globally. However, the evidence for geographical 
variation in Subtype-C isolates means that our findings may not translate to 
Subtype-C outside of Sub-Saharan Africa. As this study is the first to look at 
the Tat protein in stroke in South Africa, we hope that it may prompt research 
in other geographical regions, to see whether similar amino acid variations 
exist in stroke patients elsewhere.  
6.10.7 In vitro studies  
Functional studies of the identified signature amino acids were not in the scope 
of this research project. Functional analysis would have enabled us to 
determine whether these amino acid substitutions altered the action of the Tat 
protein on endothelial cells in vitro. However, in vitro studies are not always 
transferable to the biological activity of the protein in vivo. The difficulty of 
ascertaining which amino acid substitutions are clinically relevant is 
demonstrated by the debate around the C31S mutation in the Tat protein. The 
C31S motif, thought to be the cause of reduced neurovirulence and pro-
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inflammatory properties in vitro, has more recently been demonstrated to have 
less clinical or neuroimaging relevance than was originally postulated 
(Campbell et al., 2007; Paul et al., 2014, 2017; Dara et al., 2015). 
 
6.11. Summary of discussion  
 
Chronic persistent inflammation in HIV is a prominent driver of endothelial 
dysfunction, and contributes to the elevated risk of cardiovascular disease and 
ischaemic stroke in these individuals (Feinstein et al., 2016). HIV-associated 
endothelial dysfunction and HIV-associated vasculopathy are thought to be 
due to the inflammatory state generated by the effects of the virus.  
 
This study demonstrated that there were multiple factors that may cause 
inflammation and endothelial dysfunction to reach a critical threshold at which 
thrombosis and occlusion occur, and that the Transactivator of Transcription 
protein may have a role in HIV-associated inflammation and endothelial 
dysfunction.  
• Young HIV-infected individuals with acute ischaemic stroke have a 
higher prevalence of traditional cardiovascular risk factors compared 
with those without stroke.  
• Immunocompromise is a significant risk factor for ischaemic stroke: a 
low CD4 nadir, low CD4 count, treatment interruption and high viral load 
are associated with ischaemic stroke.  
• The majority of strokes in young, immunocompromised HIV-infected 
individuals are caused by certain forms of HIV-associated vasculopathy 
and opportunistic infections, and in this study, were associated with a 
lower recent CD4 count, and not with IRIS.   
• The various forms of HIV-associated vasculopathy occur at a range of 
CD4 counts, with a tendency for non-atherosclerotic vasculopathy and 
HIV-associated vasculitis to occur at CD4 counts < 200 cells/µl. The 
forms of HIV-associated vasculopathy that occur at higher CD4 counts 
 132 
may need additional risk factors to reach a critical threshold at which 
stroke occurs.  
• Specific amino acids at positions 21 and 29 in exon 1 of the HIV-1 Tat 
protein are associated with ischaemic stroke and could contribute to 
HIV-associated endothelial dysfunction and HIV-associated 
vasculopathy by increasing viral replication and chemoattraction of 
inflammatory cells to the vascular endothelium. These signature 
residues were also shown to modulate IL-6 and MCP-1, which are key 
pro-inflammatory biomarkers.  
• A signature amino acid at position 58 in exon 1 of the HIV-1 Tat protein 
distinguishes strokes due to alternative mechanisms from strokes due 
to HIV-associated vasculopathy. The differences in stroke aetiology 
may be related to the modulation of chronic persistent inflammation by 
Tat protein variants.  
 
The study does have limitations, which include a fixed sample size, potential 
sampling bias, and lack of in vitro studies. However, it was always intended to 
be a preliminary exploration into the association of Tat protein variants with 
ischaemic stroke, and to assess the potential for further research. The study, 
with its depth of clinical information accompanying the viral protein analysis, 
has provided information about the Tat protein, as well as synergistic risk 
factors that may influence ischaemic stroke in young South African HIV-












CHAPTER SEVEN: CONCLUSION 
 
 
This study is, to our knowledge, the first to look at the Tat protein in the clinical 
context of HIV-associated acute ischaemic stroke. It has added to the growing 
body of knowledge around the impact of HIV-1 proteins on disease risk and 
pathogenesis in HIV-infected individuals.  
 
The exact pathogenesis of HIV-associated endothelial dysfunction and the 
extent of its contribution to the development of ischaemic stroke is still unclear. 
It is acknowledged that HIV-associated inflammation and endothelial 
dysfunction have a prominent, and, in some individuals, independent role in 
the pathogenesis of ischaemic stroke.  
 
A state of chronic persistent inflammation has become synonymous with HIV 
infection, and likely underpins HIV-associated endothelial dysfunction. Most 
HIV-infected individuals have a degree of HIV-induced endothelial dysfunction, 
the extent and progression of which may be determined by several factors.  
HIV-associated endothelial dysfunction, represented by HIV-associated 
vasculopathy, may be sufficient to produce clinical ischaemia, or may need 
additional factors to reach a critical threshold at which thrombosis and 
occlusion occur.  
 
I conducted a cross-sectional analysis of two groups: cases which had reached 
this critical threshold and developed ischaemic stroke, and a control group, 
which had not. A large proportion of the entire cohort was virally unsuppressed, 
making it highly likely that individuals in both groups had a degree of HIV-
associated endothelial dysfunction. However, there were several factors that 
distinguished the stroke from the control group which could have enhanced 
the progression of endothelial dysfunction to thrombosis, occlusion, and 
clinical ischaemia. 
 
Firstly, the severity of HIV-associated endothelial dysfunction in the stroke 
group could have been influenced by their lower CD4 count, lower CD4 nadir, 
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higher viral load and higher rate of treatment interruption. Secondly, the stroke 
group had a higher prevalence of certain cardiovascular risk factors, and 
specific opportunistic infections, which could have acted synergistically with 
the virus to enhance inflammation and oxidative stress on the vascular 
endothelium. Finally, the focus of this study was the HIV-1 Tat protein, and its 
potential to contribute to HIV-associated endothelial dysfunction. Sequence 
analysis in this cohort demonstrated that there were indeed genetic attributes 
of the Tat protein that distinguished the stroke group from controls. The two 
signature amino acids identified were in regions important for viral replication 
and chemoattraction of inflammatory cells to the vascular endothelium. 
Furthermore, statistical analysis demonstrated that different residues at these 
signature positions were associated with biomarkers of inflammation, 
supporting the idea that the Tat protein may indeed be integral to the 
development of HIV-associated endothelial dysfunction and stroke.  
 
This study, conducted at the epicentre of the HIV-epidemic, demonstrated that 
amino acid variations in the HIV-1 Subtype-C Tat protein may have a role in 
HIV-associated endothelial dysfunction. Overall, the clinical and virological 
findings also support the idea that the severity of HIV-associated endothelial 
dysfunction, and an individual’s progression to clinical ischaemia, is likely to 













Figure 7.1. Model for the progression of HIV-associated endothelial dysfunction to stroke. Variants in the Tat protein may increase inflammation. Multiple 
factors can independently or cumulatively contribute to a threshold at which thrombosis and occlusion occurs.  
*These factors may independently cause stroke in HIV  
Images adapted from https://thumbs.dreamstime.com/z/normal-artery-inflamed-narrowed-artery-artery-aneurysm-cross-section-57964874.jpg and 
http://78.media.tumblr.com/2d15aba34db2a245a96175f709a0cfed/tumblr_inline_n2mydp7hNb1r41umo.jpg 
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Appendix C: Classification of arterial ischaemic stroke in 
HIV 
 
(Benjamin, Bryer, et al., 2016) 
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